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Summary	
Evolution has provided us with the possibility to avoid potentially damaging environmental 
impacts. Those eventual or actual damaging events are sensed by specialized sensory 
neurons called nociceptors. Nociceptive signals generated in the peripheral tissue travel from 
there to the first relay center in the central nervous system, the spinal cord. Here, the 
information is decoded, filtered or amplified, and eventually conveyed to the brain, where the 
conscious sensation of pain is formed. Malfunctioning of this nociceptive system can lead to 
persistent pain without apparent benefit. Diminished inhibitory neurotransmission in the 
superficial spinal dorsal horn is a pivotal event in the generation and maintenance of 
pathological pain syndromes. Recent studies have shown that spinal disinhibition can arise 
from decreased glycinergic and γ-aminobutyric acid (GABA)ergic neurotransmission. 
Accordingly, pharmacological enhancement of glycinergic or GABAergic synaptic inhibition in 
the spinal dorsal horn should be well-suited to restore proper inhibition and eventually have a 
beneficial effect on chronic pain syndromes. However, in order to avoid side effects 
originating from supraspinal sites, strategies need to be developed that restrict these 
interventions to the spinal cord. Targeting glycine receptor or GABAA receptor (GlyRs or 
GABAARs) subtypes that are specifically expressed or enriched in the spinal cord may 
provide such opportunities.  
In the first part of this thesis, I investigated the modulation of GlyRs by the non-anaesthetic 
propofol derivative 2,6-di-tert-butylphenol (2,6-DTBP). I found that 2,6-DTBP reverses 
inflammation-mediated disinhibition through a specific interaction with heteromeric 
phosphorylated synaptic α3βGlyRs. Using electrophysiological techniques, I demonstrated 
that recombinant homomeric α3GlyRs are sensitive to the modulation of 2,6-DTBP. However, 
the inclusion of the β subunit to the receptor complex dampens the sensitivity to 2,6-DTBP. 
Our molecular modelling suggests that in heteromeric α3βGlyRs this modulatory site is 
accessible to 2,6-DTBP only after a PKA-dependent phosphorylation. In native mouse spinal 
cord tissue, 2,6-DTBP modulated synaptic GlyR currents only after priming with PGE2, 
consistent with our molecular modelling data. In mouse models of inflammatory pain, 2,6-
DTBP reduced inflammatory hyperalgesia in an α3GlyR-dependent manner. These data 
suggest that an additional level of selectivity can be reached targeting inflammation-primed 
α3GlyRs, reducing the likelihood of off-target effects. 
The second part of my thesis was directed to characterize the modulatory activities of 
selected (non- or less sedative) benzodiazepine-binding site ligands (BDZs) acting at 
canonical and non-canonical BDZ-binding site of GABAARs. Several lines of evidence 
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demonstrate the importance to target α2-cointaining GABAARs for the analgesic effects of 
BDZs over α1GABAARs, which mediate the sedative effects. I therefore aimed to 
characterize selected BDZs in order to find compounds with an α2/ α1 selectivity ratio. 
Canonical BDZ-binding sites are formed by the interface of one out of four α subunits (α1, 
α2, α3, or α5) and the γ2 subunit. I found that N-desmethyl clobazam (NDMC), the main 
metabolite of the licensed anti-epileptic drug clobazam (CBZ) possess better selectivity to the 
antihyperalgesic α2-containing GABAARs over the classical BDZ diazepam (DZP). Among 
the six compounds tested, imidazotriazine TPA023B showed the best α2/α1 ratio, in 
agreement with previous findings. Non-canonical BDZ-binding sites are made up by ‘non-
γ2’GABAARs. Among the three γ subunits, γ1 is also expressed at potentially relevant levels 
in the spinal cord, and its localization and expression in the brain is lower compared to γ2. In 
addition, there is evidence indicating that other factors in addition to the α subunit subtypes 
contribute to the pharmacodynamic profile of BDZs. I therefore characterized the activities of 
several non- or less sedative BDZs at γ1-containing GABAARs. The benzodiazepine HZ-166 
showed a higher efficacy at γ1GABAARs than at γ2GABAARs. When compared to other 
BDZs, HZ-166 showed the highest γ1 efficacy at sub-saturating concentrations. HZ-166 
compound might therefore be useful to test antihyperalgesic effects of spinal γ1GABAARs.  
Taken together, this thesis describes a novel mechanism for specific pharmacological 
targeting of “pain relevant” GlyRs and identified a new tool for the analysis of γ1GABAARs in 
spinal pain control.  
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Zusammenfassung	
Die Evolution hat uns mit einem Mechanismus ausgestattet, der es uns erlaubt potentiell 
gefährliche und schmerzvolle Umwelteinwirkungen auf den Körper zu vermeiden. Diese 
Reize werden durch spezialisierte sensorische Neurone, den Nozizeptoren in den peripheren 
Geweben, wahrgenommen. Von den Nozizeptoren aus wird die Reizinformation an das im 
Rückenmark gelegene Hinterhorn weitergeleitet, wo sie zum ersten Mal auf eine 
nachfolgende Nervenzelle umgeschaltet wird. Das Umschalten auf die nächste Nervenzelle 
dient neben der Weiterleitung zum Hirn als Filter, Entschlüssler and Amplifikator des Reizes. 
Im Gehirn wird die Sinnesinformation dann schliesslich bewusst wahrgenommen und weiter 
verarbeitet. 
Störungen in diesem System können zu einem anhaltenden Schmerz ohne sichtbaren 
Nutzen führen. Eine solche Störung ist zum Beispiel eine verminderte neuronale Hemmung 
in den oberen Schichten des Hinterhorns. Studien haben gezeigt, dass eine Enthemmung 
durch reduzierte glyzinergische und GABAergische (ߛ-Aminobuttersäure) Neurotransmission 
zu einem solchen pathologischen Schmerzempfinden führen kann. Dementsprechend sollte 
das Gegenteil, die Verstärkung der synaptischen Hemmung durch Glyzin und GABA, mittels 
pharmakologischer Substanzen zu einer Verminderung des chronischen Schmerzleidens 
führen. Um Nebenwirkungen supraspinalen Ursprungs zu vermeiden braucht es eine 
Strategie, um die pharmakologische Intervention im Bereich des Rückenmarks 
einzuschränken. Eine Möglichkeit dafür, wäre zum Beispiel Glyzin-Rezeptoren (GlyRen) oder 
GABAA-Rezeptoren (GABAARen), welche spezifisch im Rückenmark exprimiert oder 
angereichert sind, zu modifizieren. 
 
Im ersten Teil der Dissertation habe ich die Modulation der GlyRen durch 2,6-di-tert-
butylphenol (2,6-DTBP), einem Propofol Derivat, erforscht. Eine entzündugnsinduzierite 
Enthemmung im Hinterhorn konnte durch die Interaktion von 2,6-DTBP mit heteromeren und 
phosphorylierten α3βGlyRen rückgängig gemacht werden. Meine elektrophysiologischen 
Experimente zeigen, dass rekombinante homomerische α3GlyRen durch 2,6-DTBP 
moduliert werden können, die Einführung der β-Untereinheit jedoch die Sensitivität zu 2,6-
DTBP schwächt. Unser molekularbiologisches Model geht davon aus, dass die 
Modulationsstelle im heteromeren α3βGlyRen nur dann für 2,6-DTBP zugänglich ist, wenn 
der Rezeptor durch das PKA Enzym phosphoryliert wurde. Wie durch unser Modell 
vorhergesagt, konnten im Rückenmark einer nativen Maus die GlyR-Ströme nur durch 
vorherige Inkubation mit PGE2 durch 2,6-DTBP moduliert werden. In Mausmodellen für 
7 
 
Entzündungsschmerz konnte 2,6-DTBP durch die Modulation an α3GlyRen den Schmerz 
mindern. Diese Daten zeigen, dass ein zusätzliches Level an Selektivität gewonnen werden 
kann, wenn entzündungsaktivierte α3GlyRen für die pharmakologische Modulation angepeilt 
werden. 
 
Der zweite Teil meiner Dissertation war der Charakterisierung der modulierenden Tätigkeiten 
von ausgewählten (nicht oder wenig sedativen) Benzodiazepin (BDZ) Bindungsstellen-
Liganden gewidmet. Diese wirken auf kanonische und nicht-kanonische BDZ-
Bindungsstellen der GABAARen. Verschiedene Hinweise deuten auf die Wichtigkeit der 
bevorzugten Bindung von BDZs an α2-enthaltende GABAARen für die schmerzlindernden 
Effekte, anstelle von α1GABAARen, welche für den sedativen Effekt verantwortlich sind. Ich 
habe deshalb ausgewählte BDZs charakterisiert, um Präparate mit einem grossen α2/α1 
Selektivitätsverhältnis zu finden. Die kanonischen BDZ-Bindungsstellen werden durch 
Kopplung von einer von vier α-Untereinheiten (α1, α2, α3 oder α4) und der γ2-Untereinheit 
gebildet. Ich habe herausgefunden, dass N-Desmethylclobazam (NDMC), das wichtigste 
Abbauprodukt des lizenzierten Epilepsie-Medikaments Clobazam (CBZ), eine höhere 
Selektivität für den anti-hyperalgetischen, α2-enthaltenden GABAA-Rezeptor als das 
klassische BDZ Diazepam (DZP) hat. Unter den sechs getesteten Stoffen wies 
Imidazotriazin TPA023B das beste α2/α1 Verhältnis auf. Diese Beobachtungen stimmten mit 
früheren Ergebnissen überein. Die nicht-kanonischen BDZ Bindungsstellen sind aus ‘nicht-
γ2’-haltigen GABAARen aufgebaut. Von den drei γ-Untereinheiten erreicht nur die γ1-
Untereinheit in der Wirbelsäule ein potentiell relevantes Expressionsniveau, während im 
Gehirn γ2 höher exprimiert ist. Zusätzlich gibt es Hinweise dafür, dass noch andere Faktoren 
zusätzlich zu den α-Untereinheiten zum pharmakodynamischen Profil von BDZs beitragen. 
Ich habe deshalb die Aktivität von mehreren nicht oder wenig sedativen BDZs auf γ1-
enthaltende GABAARen untersucht. Das Benzodiazepin HZ-166 zeige hierbei eine höhere 
Wirksamkeit bei γ1GABAARen als bei γ2GABAARen. Verglichen mit anderen BDZs zeigte 
HZ-166 die höchste Wirksamkeit an γ1GABAARen bei Konzentrationen unter dem 
Sättigungspunkt. HZ-166 könnte deshalb genutzt werden um die anti-hyperalgetischen 
Effekte von spinalen γ1GABAARen zu untersuchen. 
Zusammengenommen beschreibt diese Dissertation einen neuen Mechanismus für die 
spezifische pharmakologische Interaktion mit «schmerzrelevanten» GlyRen, sowie ein neues 
Werkzeug zur Analyse von γ1GABAARen in der spinalen Schmerzkontrolle 
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Abbreviations	and	chemical	names	
2,6-DTBP , 2,6-ditertbutyl phenol  
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L-838,417. 3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-
yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine  
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LTD, long term depression 
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NDMC, N-desmethyl clobazam 
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PGE2, prostaglandin E2 
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TP003, 5-fluoro-2-[4-fluoro-3-[8-fluoro-7-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-
yl]phenyl]benzonitrile 
TPA023B, 6,2′-difluoro-5′-[3-(1-hydroxy-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-
yl]biphenyl-2-carbonitrile 
TRP, transient receptor potential 
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1.	General	Introduction	
A 	BRIEF	HISTORY	OF	PAIN	
When Aristotle numbered the five senses, he left out Pain. He, and his master Plato, thought 
that pain is not a sensory experience, but an emotional one, placing the heart as the central 
organ for this experience. Pain seemed to be carried by external beings or spirits entering 
through the injury commanded by gods in a sort of punishment. This supernatural conception 
of pain was then refuted during the Renaissance by René Descartes. He imagined the 
human body as a machine. He proposed that pain is a mechanical activation of a single 
cable from the site of the disturbance directly to the brain. Therefore, the understanding of 
pain moved from a mystical experience to a natural, internal one; from the heart to the brain.  
The first half of the 20th century witnessed the developing of two new theories based on the 
work from Max von Frey and Alfred Goldscheider. On one hand, the ‘sensory theory’ holding 
that different nerves convey different types of information, being pain a specific modality like 
hearing and vision; and on the other hand, the ‘pattern theory’, stating that any kind of 
sensory stimulus being intense enough would elicit pain. The concept of the specificity theory 
is still alive and builds the basis of the labelled line hypothesis (Craig, 2003), which proposes 
that dedicated sensory neurons and neuronal projections exist for the different 
somatosensory sensations. A more complex concept proposing an interaction of nociceptive 
and non-nociceptive signals has been developed by Patrick Wall and Ronald Melzack in their 
famous gate control theory of pain. This theory states that neurons located in the substantia 
gelatinosa of the spinal dorsal horn function as a gate control system that modulates the 
outcome of a painful stimulus to the brain. This concept had a major impact on our current 
understanding of pain. 
 
GENERAL	FEATURES	OF	PAIN	
The international society of the study of pain (IASP) defines pain as ‘an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or described in 
terms of such damage’ (Bonica, 1979). In children born with congenital disability to 
experience pain, severe injuries often go unnoticed and can lead to repeated and potentially 
irreversible tissue damage and even death (Cox et al., 2006). Given the fact that pain also 
has an affective and emotional component, the perception of pain is subjective and also 
influenced by many factors. For instance, injured athletes are often not aware of pain until 
the match is over. Therefore, pain is not only a sensory experience, but rather the result of a 
complex processing of diverse neural signals by the brain including emotional cues.  
  General Introduction 
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Nature has provided us with the ability to perceive acute noxious threats, triggering protective 
reflexes and increasing our awareness. Usually, intense mechanical (noxious pressure, 
noxious movements, etc.) or thermal stimuli (noxious heat, noxious cold) are necessary to 
activate the nociceptive system, and when stimulated, physiologic nociceptive pain is elicited. 
However, during inflammation processes or tissue injury, pathophysiologic nociceptive pain 
is evoked. This inflammatory pain is characterized by mechanical and/or thermal allodynia 
and hyperalgesia.  Allodynia refers to pain evoked by innocuous stimuli as light touch, 
whereas hyperalgesia describes a state of increased sensitivity to stimuli that are sensed as 
painful under normal conditions. In the course of inflammatory pain, the nociceptive system 
undergoes significant changes, but its functions are intact. On the other hand, pain can result 
from damage of neurons of the somatosensory system. This type of pain is called 
neuropathic pain.  
THE	NOCICEPTIVE	SYSTEM	
To better understand the neural processes underlying the perception of pain, it is necessary 
to have a look at the nociceptive neuroanatomy. Many organs in the periphery, including 
skin, muscles and joints, possess specialized sensory receptors, called primary nociceptors, 
which are activated by noxious stimuli. They convert noxious stimuli into electrical signals 
delivering these signals into the spinal cord or brain stem. The information is further 
conveyed to higher CNS areas where the conscious experience of pain takes place (Figure 
1). 
General Introduction 
12 
 
 
Figure 1. Schematic diagram of the spinal pain pathway. Nociceptive signals are conveyed to the 
central nervous system by the nociceptors (high-threshold primary sensory neurons), whose somata 
are located in the dorsal root ganglia (DRGs). They make contact to dorsal horn (DH) neurons in the 
spinal cord or brain stem, which in turn transmit the nociceptive information to supraspinal centers, 
including the rostral ventromedial medulla (RVM), the parabrachial nucleus (PbN), the periaqueductal 
grey (PAG) and thalamus (Th). Neurons in the cortex make contact with the hypothalamus (HT) and 
PAG, which control the RVM. From the RVM, descending tracts eventually control spinal nociception. 
Modified from Zeilhofer et al., 2015 
Peripheral nociceptors 
Exposure to a noxious stimulus depolarizes the primary nociceptors terminals in the 
periphery through the opening of specific ion channels (Waxman and Zamponi, 2014). This 
depolarization, if strong enough, opens voltage-gated sodium channels (e.g. Nav1.8), which 
then elicit action potentials travelling along the fiber from their terminal in the periphery, 
through the DRG to the dorsal horn of the spinal cord. Here, the central terminals of the 
primary nociceptors make synapses with second order neurons located in different layers of 
the spinal dorsal horn. 
Innocuous information is carried by myelinated A fibers. Most of the nociceptors are thinly 
myelinated A fibers or unmyelinated C fibers. These fibers differ in their electrical properties. 
C fibers have a conduction velocity of 0.5 – 2 m/s, which is slower than the myelinated A 
fibers (12 – 30 m/s). A fibers exhibit conduction velocities between 30 - 70 m/s 
  General Introduction 
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(Markopoulos, 2010). These distinct velocities reveal the type of pain that is driven by these 
fibers. For instance, A fibers account for the sharp and localized pain sensation, while C 
fibers elicit a slower, dull and more diffuse sensation. 
By the use of various neurochemical markers, C fibers are further subdivided into 
peptidergic, which express calcitonin gene-related peptide (CGRP) or substance P (SP), and 
non-peptidergic, which are characterized by the binding of isolectin B4 (IB4). C fibers may 
have distinct physiological roles. Peptidergic C fibers have been implicated in thermal 
nociception (McCoy et al., 2013), whereas non-peptidergic C fibers in mechanical (Bogen et 
al., 2008) and also thermal (Malin et al., 2006) nociception. The peripheral endings of these 
nociceptors harbor specific receptors and ion channels, which mediate different sensory 
information. For instance, sensitivity to heat partially depends on the transient receptor 
potential (TRP) vanilloid type 1 and 2 (V1/2), cold sensing arises mainly through activation of 
TRP menthol 8 (TRPM8) and/or TRP Ankyrin 1 (TRPA1) (Julius and Basbaum, 2001). In the 
dorsal spinal cord, these different primary afferent fibbers terminate in a characteristic pattern 
ordered in layers.  
Spinal cord 
The Swedish neuroscientist Bror Rexed identified in the early 1950s a system of ten distinct 
layers in the grey matter of the spinal cord (Rexed, 1952) (Figure 2A).  The particular 
organization of the dorsal horn of the spinal cord goes along with defined primary afferents 
input patters (Figure 2B). Lamina I is the most superficial layer of the spinal cord. This lamina 
mainly harbors projection neurons, which can be identified by the expression of neurokinin 1 
receptor (NK1-R). Neurons within lamina I are responsive to noxious stimuli, via A and 
peptidergic C fibers. Virtually all of the neurons in lamina II are interneurons, e.g. their axons 
remain in the spinal cord and arborize locally. Interneurons can be divided into two main 
classes: excitatory (glutamatergic) and inhibitory (GABAergic and glycinergic). The inhibitory 
population in lamina II is one third of the total number present in this lamina. Neurons in 
lamina II are also responsive to either noxious or innocuous stimuli. Neurons located in the 
most dorsal part (lamina IIo) receive inputs from peptidergic C fibers. In contrast, non-
peptidergic C fibers make contact with neurons located in the mid-region of lamina II (Braz et 
al., 2005). The most ventral part (lamina IIi) is characterized by interneurons expressing 
protein kinase C isoform  (PKC), which are targeted by myelinated non-nociceptive primary 
afferents (Neumann et al., 2008). Laminae III and IV contain a mixture of local interneurons 
and supraspinal projection neurons. Many of these neurons are primary responsive to 
innocuous stimuli (via A fibers). Neurons in lamina V respond to a wide variety of noxious 
stimuli via direct A and A (monosynaptic) inputs and indirect C fiber (polysynaptic) inputs. 
General Introduction 
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Figure 2. Architectonic organization of the spinal cord. (A) Rat spinal cord neurons labeled with 
NeuN. Dashed lines correspond to the Rexed division of laminar boundaries. (B) Scheme of the 
laminar termination patter of primary afferents. Reproduced from (Todd, 2010), with permission. 
Ascending Pathways, supraspinal pain territories  
Projection neurons are mainly present in lamina I and scattered throughout lamina III-VI. 
Many of these neurons project their axons crossing the midline and travel rostrally in the 
contralateral white matter to terminate in various brainstem and thalamic nuclei, establishing 
the spinoreticulothalamic and spinothalamic tracts, respectively. 
Using anterograde and retrograde tracing it has been revealed that main targets for lamina I 
projection neurons include the caudal ventrolateral medulla (CVLM), the periaqueductal grey 
matter (PAG), the nucleus of the solitary tract (NTS), and certain nuclei in the thalamus 
(Gauriau and Bernard, 2004) 
From these brainstem and thalamic loci, nociceptive information travels towards cortical 
territories. Unlike any other sensory modalities, a single specific brain area cannot be 
attributed to pain sensation (Apkarian, 2013). Nevertheless, some regions have been 
described to be involved in certain features of pain. For instance, the somatosensory cortex 
may be involved in the sensory-discriminative properties (Auvray et al., 2010); the anterior 
cingulate and insular cortex are associated to emotional aspects (Gao et al., 2004); and both 
the insula and prefrontal cortex are involved in cognitive processing of pain (Kong et al., 
2006). However, some other regions not related to pain processing, like basal ganglia and 
cerebellum, have been shown to be also activated (Basbaum et al., 2009). 
Descending pathways   
From supraspinal territories, descending fibers can project onto the dorsal spinal cord 
modulating spinal pain processing (Gebhart, 2004). This regulation is primarily done by 
  General Introduction 
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monoaminergic pathways from several supraspinal sites (Millan, 2002). Classical studies 
have suggested an important role of PAG on descending pathways-mediated analgesia 
(Reynolds, 1969, Yaksh and Rudy, 1978). Following research demonstrated that the PAG is 
part of a central circuit that controls nociceptive transmission via a relay in the rostral 
ventromedial medulla (RVM) (Fields and Heinricher, 1985). This connection is critical for 
descending pain modulation (Fields et al., 1991). RVM connects to the spinal cord through 
serotoninergic and GABAergic neurons. Their axons project to dorsal horn lamina I, II and V; 
as stated previously, these laminae are targets of nociceptive primary afferents. According to 
morphological and electrophysiological evidence, RVM neurons regulate nociception via 
several mechanisms including direct inhibition of projection neurons, reduction of 
neurotransmitter release from nociceptive fibers, increase of excitation of inhibitory 
interneuron, and inhibition of excitatory interneurons (Todd, 2010). However, functional 
studies have demonstrated that brainstem modulatory mechanisms are bidirectional, in that 
not only inhibit nociception but also elicit pain facilitation (reviewed in Porreca et al., 2002). 
For instance, RVM has been shown to be implicated in hyperalgesia and chronic pain as part 
of a possible positive feedback loop stimulated by noxious input. 
CELLULAR	AND	MOLECULAR	MECHANISMS	OF	PATHOLOGICAL	PAIN	
Pain therapy is relevant to most fields of medicine since pain is a co-morbidity of numerous 
diseases. It is estimated that 20 % of the European population suffer from chronic pain, 
where osteoarthritis pain and low back pain are the leading causes (Breivik et al., 2006). Two 
thirds of chronic pain patients report that their therapy against pain is not successful and, in 
many cases, it leads to depression and inability to work. The Institute of Medicine in the USA 
reports that the number of patients suffering of chronic pain outnumbers patients suffering 
from cancer, diabetes and heart disease combined (Scholz and Woolf, 2002). This brings 
along a monetary burden of about $ 635 billion in medical treatment and loss of productivity. 
Therefore, intense pain research is necessary to improve patients’ well-being. A major goal 
of pain research is to elucidate the neuronal mechanisms underlying the generation and 
maintenance of pain. As described previously, pain is determined by neurophysiological 
mechanisms in the nociceptive system as well as by psychological and socio-cultural 
influences. Thus, advanced understanding of the processes integrating the clinical symptoms 
of pain is a key step towards identifying the mechanisms that can be targeted for pain 
treatment. Chronic pathological pain can be initiated or maintained at peripheral and/or 
central regions.  
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Peripheral sensitization 
During the course of inflammation or after tissue damage, primary nociceptors undergo 
plastic changes. They not only develop lower sensory thresholds to different mechanical 
and/or thermal stimuli, but also start to fire action potentials at higher frequencies (Schaible 
and Richter, 2004). During an inflammatory process, resident cells, such as keratinocytes 
and mast cells, also release inflammatory mediators, including prostaglandins, protons, ATP, 
bradykinin, nerve growth factor (NGF), interleukins, histamine and serotonin, which directly 
activate and modulate numerous ion channels and receptors located in nociceptive nerve 
fibers. These pro-inflammatory molecules trigger a hyperalgesic priming state (reviewed in 
Reichling and Levine, 2009). A very well-characterize inflammatory mediator is NGF. NGF 
activates TrkA receptors (receptor tyrosine kinase A, tropomyosin-related kinase A) leading 
to the activation of several signaling cascades, which in turn, will increase the expression of 
certain genes involved in nociceptors hypersensitivity, for instance, TRPV1, bradykinin 
receptors, sodium channels, substance-P and CGRP (Woolf, 1996, Fjell et al., 1999). 
Peripheral sensitization, therefore, leads to primary hyperalgesia, which is a localized 
sensitization at the area of tissue damage. The increase in nociceptive transmission from the 
periphery induces secondary changes in the central nervous system (CNS). 
Central sensitization 
Central sensitization results from changes in excitability of CNS neurons being fundamental 
for the generation of allodynia, secondary hyperalgesia and spontaneous pain (Latremoliere 
and Woolf, 2009, Sandkuhler, 2009, Kuner, 2010). Secondary hyperalgesia refers to a form 
of sensitization occurring in an area surrounding the site of inflammation and nociceptor 
activation. This secondary hyperalgesia is not accompanied by increased in nociceptor 
excitability but rather caused by changes in central pain processing.  
Central sensitization was demonstrated in human volunteers by intradermal capsaicin 
injection. It was then established that heat pain at the zone of injection, was carried by C 
fibers, whereas the secondary mechanical hyperalgesia and allodynia was transferred to the 
CNS by A mechanoreceptors and low threshold myelinated fibers, respectively (Torebjork et 
al., 1992). A large number of studies have identified that central sensitization contributes to 
several pain phenotypes, including rheumatoid arthritis (RA), osteoarthritis  (OA), 
fibromyalgia (FM) and neuropathic pain (for review see Woolf, 2011).  
This change in central pain processing can be caused by several cellular and molecular 
mechanisms, including development of long-term potentiation (LTP) of excitatory synapses 
and a reduction of GABAergic and or glycinergic inhibitory neurotransmission (disinhibition).   
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Increase of spinal synaptic strength  
Synaptic strength refers to the magnitude of a post-synaptic response, in terms of currents or 
potentials, upon activation of pre-synaptic neurons. This synaptic strength can be modified 
by the quality of pre-synaptic inputs, either by high or low frequency activity of those inputs. 
In the hippocampus, it has very well described that a high frequency stimulation of pre-
synaptic neurons (or fibers) can trigger LTP (Bliss and Lomo, 1973). However, these plastic 
changes in synaptic response have not only been seen in brain areas, but also in the spinal 
cord. Spinal LTP can be triggered by intense C fiber input (in a use use-dependent manner) 
to lamina I projection neurons (Sandkuhler et al., 1997, for review see Sandkuhler, 2009). 
Therefore, this mechanism of synaptic strength at spinal cord has been correlated to learning 
and memory formation in the hippocampus. As in the hippocampus, spinal LTP also depends 
on N-methyl D-aspartate receptors (NMDARs) and T-type voltage-gated calcium channels 
(Ikeda et al., 2003), and involves the insertion of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) into glutamatergic synapses. This strengthened 
spinal synaptic transmission can also be induced in vivo by capsaicin or formalin injection in 
peripheral territories, as well as peripheral inflammation and nerve injury (Randic et al., 1993, 
Ikeda et al., 2003). It is quite likely that similar forms of plasticity exist in supraspinal 
territories, including synapses in the cerebral cortex (Li et al., 2010, Zhuo, 2011) 
Disinhibition 
About one-third of in the spinal dorsal horn are inhibitory. These neurons release GABA 
and/or glycine to promote inhibition of the post-synaptic cells by inducing a chloride 
conductance through ionotropic GABAA and glycine receptors, respectively, and therefore 
hyperpolarizing the cell. It is also worth noting that GABA can activate metabotropic GABAB 
receptors, which trigger inhibition through facilitating the opening of G protein-coupled 
inwardly-rectifying potassium (GIRK) channels in the post-synaptic cell, and by inhibiting 
voltage-gated calcium channels in the pre-synaptic neuron.  
The concept of inhibition in spinal pain processing was firstly proposed in the gate control 
theory of pain (Melzack and Wall, 1965). This theory, in its original version, suggested that 
inputs arriving to the dorsal spinal cord from low-threshold mechanoreceptors and high-
threshold nociceptors interact with intrinsic inhibitory neurons to open or close the pain gate. 
Therefore, they proposed a pivotal role of inhibitory interneurons in the spinal control of 
nociceptive signal propagation. About 20 years later, the first experimental proof implicating 
an endogenous inhibitory control by GABAergic and glycinergic neurotransmission was 
performed by testing the effects of spinal application of specific blockers of GABAARs and 
glycine receptors. Animals spinally injected with theses antagonists responded with 
symptoms of hyperalgesia and of allodynia along with spontaneous pain (Beyer et al., 1985, 
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Roberts et al., 1986, Sivilotti and Woolf, 1994), as described previously, signs of central 
sensitization. A recent publication revisited the gate control theory of pain and demonstrated 
the crucial role of dorsal horn glycinergic interneurons in pain processing (Foster et al., 
2015). 
In pathological pain states GABAergic and glycinergic inhibition can get compromised in 
neuropathic pain as well as in inflammatory pain through a variety of mechanisms which I will 
describe below.  
Activation of microglia by mediators, such as chemokine (C-C motif) ligand 2 (CCL2), 
released from the central terminals of primary afferents is one initiating event leading to 
diminished inhibitory neurotransmission in response to peripheral nerve damage (Zhang and 
De Koninck, 2006). Brain-derived neurotrophic factor (BDNF), released by activated 
microglia, downregulates the expression of the potassium/chloride cotransporter KCC2, 
which plays an important role on maintaining low intracellular chloride concentration. This 
increase of chloride concentration decreases (or even reverses) the hyperpolarizing action 
GABA and glycine due to the shift in the chloride reversal potential towards more depolarized 
voltages (Coull et al., 2003, Coull et al., 2005). 
After nerve injury, an incomplete loss of the GABA synthesizing enzyme GAD65 in the dorsal 
spinal cord occurs (Moore et al., 2002, Lorenzo et al., 2014). The consequence of this is a 
depletion of GABA in inhibitory boutons, leading to diminished inhibition. Moreover, in 
persistent inflammatory and neuropathic pain states, the transcription of the gene encoding 
for GAD65 (GAD2) is epigenetically suppressed through histone deacetylase (HDAC)-
mediated histone hypoacetylation (Zhang et al., 2011)  
Secondary hyperalgesia and allodynia caused by intraplantar injection of capsaicin in mice is 
at least partially mediated by a reduction of glycinergic and GABAergic inhibition. Excitatory 
nociceptive-specific interneurons receive less inhibitory post-synaptic currents (IPSCs) 
caused by spinal production of endocannabinoids (eCB) and the subsequent activation of 
cannabinoid 1 (CB1) receptors located on the presynaptic inhibitory terminal. Upon intense 
glutamatergic C fiber input, endocannabinoids, retrogradely-released from presumed 
excitatory interneurons, activate the CB1 receptors located at the inhibitory pre-synaptic 
neuron, which in turn reduce the release of inhibitory neurotransmitter (Pernia-Andrade et al., 
2009), ultimately promoting disinhibition. 
Diminished synaptic inhibition in the spinal dorsal horn also occurs in the course of peripheral 
inflammation. It has been shown that after peripheral inflammation, glycinergic 
neurotransmission is reduced (Muller et al., 2003). Prostaglandins are important mediators of 
inflammation and contribute also to central sensitization. In the spinal cord, prostaglandin E2 
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(PGE2) is produced by the inducible cyclooxygenase 2 (COX-2) from arachidonic acid. Spinal 
pronociceptive actions of PGE2 occur through PGE2 receptors of the EP2 subtype expressed 
on excitatory interneurons (Reinold et al., 2005). EP2 receptors subsequently activate protein 
kinase A (PKA) through an increase of cyclic adenosine monophosphate (cAMP). PKA 
phosphorylates glycine receptors containing the GlyRs α3 subunit (α3GlyRs), rendering 
these receptors less responsive to synaptically released glycine (Ahmadi et al., 2002, Muller 
et al., 2003, Harvey et al., 2004) (Figure 3). This decrease in GlyR activation induces 
mechanical and thermal hyperalgesia. Moreover, mice lacking the GlyRα3 subunit (GlyRα3-/-) 
show reduced sensitization and faster recovery from peripheral inflammation by Zymosan A 
and complete Freund’s adjuvant (CFA). This phenotype is specific for inflammatory pain and 
does not occur in neuropathic pain models, where mechanical and thermal hyperalgesia 
remain unchanged. PGE2-dependent disinhibition therefore appears to play a role primarily in 
inflammatory hyperalgesia (Zeilhofer et al., 2012). 
 
Figure 3. Schematic representation of the PGE2-dependent spinal disinhibition in inflammatory 
pain. Peripheral inflammation induces the expression of COX-2 and synthesis of PGE2 in the spinal 
cord. PGE2 activates EP2 receptor and promotes the activity of PKA through an increase of cAMP. 
PKA then phosphorylates and inhibits GlyRs containing the α3 subunit (GlyRα3). Modified from 
Zeilhofer et al., 2012. 
All the mechanisms mentioned above indicate that pathological pain syndromes (either from 
inflammatory origin or neuropathic cause) merge onto diminished GABAergic and/or 
glycinergic inhibition in the dorsal spinal cord. This disinhibition mimics the major symptoms 
of persistent pain conditions in human such as hyperalgesia, mechanical allodynia, and on-
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going pain. Therefore, a pharmacological enhancement of GABAergic or glycinergic 
inhibition in the spinal dorsal horn should thus have a beneficial effect on pathological pain 
syndromes. It has been shown that spinal application of the classical benzodiazepine-site 
agonist (BDZ) diazepam (DZ), which facilitates the action of GABA at GABAARs, reverses 
pathological pain sensitization in different rodent models of inflammatory and neuropathic 
pain (Knabl et al., 2008, Di Lio et al., 2011, Ralvenius et al., 2015). A thorough analysis of 
the molecular basis of GlyR and GABAAR modulation in the spinal cord along with an 
evaluation of the value of GlyR and GABAAR modulators as potential novel analgesics 
should therefore be of significant interest. 
FAST	INHIBITORY	NEUROTRANSMITTER	RECEPTORS	
In the spinal cord, the two major inhibitory neurotransmitters are glycine and GABA. 
Ionotropic glycine and GABAA receptors belong to the Cys-loop superfamily of ligand-gated 
ion channels, which also includes nicotinic acetylcholine receptors and ionotropic serotonin 
(5-HT3) receptors. Both glycine and GABAA receptors are permeable to chloride ions and to 
a lesser extent to bicarbonate (Figure 4). Glycine and GABAA receptors are formed by five 
subunits, each of them harboring four transmembrane segments (Figure 4A)  
Glycine receptors 
Glycine receptors are, together with GABAA receptors, a major inhibitory neurotransmitter 
receptor in the spinal cord, brainstem and selected supraspinal areas including the retina 
(Araki et al., 1988). The repertoire of subunits is restricted to only four  subunits (α1 - α4) 
and one β subunit (Lynch, 2004) (Figure 4B). In humans, no functional GlyRα4 subunit 
expressed due to a premature stop codon and several amino acid exchanges ((Laube et al., 
2002, Simon et al., 2004) and personal communication by Robert J. Harvey). GlyR α 
subunits can form functional homopentameric glycine-sensitive ion channel. This is not the 
case for β subunit, which, when expressed alone, does not produce glycine-gated currents. 
Heteropentameric glycine receptors composed of α and β subunits, form functional 
receptors. Their single channel conductance is less than that of homomeric receptor 
channels (Burzomato et al., 2004). The subunit stoichiometry has been subject of debate (for 
review, see Lynch, 2009), however, recent evidence suggests that the conformation of 
heteromeric α/β glycine receptors is 2α:3β (Grudzinska et al., 2005). The proper clustering of 
glycine receptors at post-synaptic sites occurs via a direct interaction between the β subunit 
and the cytoplasmic anchoring protein, gephyrin (Fritschy et al., 2008).  
During development, most of glycine receptors in the CNS are homomeric α2-containing 
receptors, which are subsequently replaced by α1β or α3β heteromers (Takahashi et al., 
1992). Homomeric α1 or α3 receptors, which cannot bind gephyrin, are more likely 
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expressed at extrasynaptic site. However, evidence from electrophysiological recordings on 
spinal neurons suggests that most extrasynaptic glycine receptors also exhibit a heteromeric 
α/β conformation (Beato and Sivilotti, 2007). Nevertheless, homomeric GlyRs might be found 
on pre-synaptic terminals controlling neurotransmitter release (Turecek and Trussell, 2001, 
Jeong et al., 2003, Deleuze et al., 2005). 
In the CNS, the α1 subunit is most abundant among the GlyR α subunits (Becker et al., 
1998), and the β subunit is also widely distributed throughout the spinal cord, retina and brain 
(Malosio et al., 1991). Therefore, most of glycine receptors at synapses are α1β 
heteropentamers. GlyR α3 subunits have been mapped to the retina and the spinal cord). 
Interestingly, in the spinal cord, expression of α3GlyRs is restricted to superficial dorsal horn 
(Harvey et al., 2004), where nociceptive fibers terminate. α3GlyRs might therefore be 
important elements of spinal inhibitory pain control. 
 
Figure 4. Inhibitory neurotransmitter receptors in the spinal cord. (A) Diagram depicting the 
subunit 4-transmembrane segments of glycine and GABAA receptors. B-C) Schematic representation 
of glycine receptor (B) and of GABAARs (C) indicating the subunit repertoire and conformation in the 
receptor complex. Red dots indicate all benzodiazepine-sensitive α subunits. 
GABAA receptors 
Mammalian GABAARs are heteropentameric ligand-gated ion channels assembled from a 
repertoire of 19 different subunits: α1 - α6, β1 - β3, γ1 - γ3, , , ,  and 1 - 3 (Figure 4C). 
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Most of GABAARs are formed with a stoichiometry of two α, two β, and one γ subunit. This 
configuration mediates phasic inhibition in the CNS. In the spinal cord, the most abundant 
configuration is α2/3, β3, γ2, whereas in the brain, most of GABAARs are composed of 
α1β2γ2 (Wisden et al., 1991, Laurie et al., 1992, Bohlhalter et al., 1996). The subunit 
arrangement determines important features of the receptor, including the affinity to GABA, 
channel kinetics, pharmacological properties and location targeting (e.g. synaptic or 
extrasynaptic). For instance, the γ2 subunit is required for the synaptic clustering of most of 
GABAAR subtypes (Essrich et al., 1998), whereas receptors incorporating the  subunit 
(together with α4/6 and β) are localized extrasynaptically, where they mediate tonic inhibition 
(for review, see Belelli et al., 2009). 
Upon release from presynaptic terminals, GABA binds to the interface between α and β 
subunit. GABAARs assemble in such a configuration that allows to set two GABA binding site 
per receptor (Figure 4C). Beside the GABA-binding sites, GABAARs also possess sites for 
modulation of endogenous neuromodulators, such neurosteroids, and exogenous 
compounds like BDZs , barbiturates, alcohols and anesthetics (Sieghart, 1995, Sigel and 
Buhr, 1997, Belelli et al., 1999, Rudolph and Mohler, 2006). Even though BDZs facilitate the 
action of GABA at GABAARs and are widely used clinically for their sedative, anxiolytic and 
anticonvulsive effects, BDZs do not exert pain-relieving actions in patients or in human 
experimental pain models (for review, see van Tulder et al., 2003; but also see Besson et al., 
2015). The BDZ-binding site is located in the interface between γ2 and α1, α2, α3 or α5 
(Figure 4C) (Mohler et al., 2001). The presence of γ1 or γ3 also allows to the binding of 
BDZs, but with strongly reduced affinities (Benke et al., 1996). 
STRATEGIES	FOR	RESTORING	GLYCINERGIC	AND	GABAERGIC	INHIBITION		
Evidence for modulators acting on GlyRs 
New evidence suggests that glycine receptors can be modulated by a number of 
compounds, including cannabinoids and general anaesthetics (for a review, see Yevenes 
and Zeilhofer, 2011a). 
Endogenously produced cannabinoid receptor ligands (endocannabinoids), such as N-
arachidonyl-ethanolaminde (anandamide, AEA) and 2-arachidonyl-glycerol (2-AG), can 
directly modulate GlyRs (Lozovaya et al., 2005, Hejazi et al., 2006, Yevenes and Zeilhofer, 
2011b). Some structurally unrelated compounds such as phyto-cannabinoids, namely 9-
tetrahydrocannabinol (THC) and cannabidiol (CBD), also exert modulating activity at GlyRs. 
A recent study (Xiong et al., 2011) has provided the first evidence of the role of GlyR 
subunits on the antihyperalgesic effects of THC. However, one important point is that 
cannabinoid-related compounds lack specificity (Oz, 2006). To overcome this, Xiong and 
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colleagues (Xiong et al., 2011) developed THC-derivatives with reduced affinity to the 
parental’s natural targets, the cannabinoid receptor (CB) 1, and CB2. Further work from the 
same group (Xiong et al., 2012a, Xiong et al., 2012b) established that cannabinoids acting 
on GlyRs suppress inflammatory and neuropathic pain, without major psychoactive side 
effects and analgesic tolerance. Furthermore, it was demonstrated that the cannabinoid-
mediated antihyperalgesic effects in pathological pain are mediated by a α3GlyR-dependent 
mechanism (Xiong et al., 2012a). 
Volatile and intravenous anaesthetics also modulate GlyRs. Many volatile anaesthetics can 
potentiate homomeric α1GlyRs, such as isoflurane, enflurane, halothane and sevoflurane 
(Downie et al., 1996, Mascia et al., 1996, Krasowski and Harrison, 1999, Yamakura et al., 
2001). Although it has been shown that α2GlyRs are also modulated (Harrison et al., 1993), 
there is no evidence on the effects of volatile anaesthetics on α3GlyRs. Intravenous 
anaesthetics, such as propofol, also modulate glycinergic function (Mascia et al., 1996, Mihic 
et al., 1997, Pistis et al., 1997, Wakita et al., 2016). The biological effects of propofol, 
however, appeared to be only by enhancing GABAergic function, rather than potentiating 
glycinergic inhibition (Sonner et al., 2003, Grasshoff and Antkowiak, 2004). Interestingly, new 
evidence has shown that propofol structural analogs, such as 4-bromopropofol and 2,6-di-
tert-butylphenol, retain modulatory effects at glycine receptor sparing activity at GABAARs 
(Krasowski et al., 2001, Ahrens et al., 2004, Ahrens et al., 2009, Eckle et al., 2014). 
The modulation of glycinergic inhibition may represent a novel therapeutic strategy to reverse 
disinhibition. According to the evidence presented above, the search for specific modulator of 
spinal synaptic α3GlyRs is a rational approach against inflammatory pain. Indeed, as 
discussed earlier, PGE2 released upon inflammation “primes” 3GlyRs, decreasing synaptic 
glycinergic current in spinal superficial dorsal horn. Compounds modulating specifically 
“primed” 3βGlyRs may, therefore, restore the glycinergic inhibition in inflammatory pain 
states, avoiding unwanted effects such as sedation.  
Evidence for modulation of GABAARs by BDZ  
In humans, benzodiazepines can exert analgesic effects when applied intraspinally through a 
modulation of BDZ-sensitive GABAARs (Tucker, 1985). However, when systemically applied, 
benzodiazepines can cause pain relief only at doses that, at the same time, cause strong 
sedation (Ralvenius et al., 2015; for review, see also Zeilhofer et al., 2009). To attribute the 
different benzodiazepine effects to identified GABAAR subtypes, point mutated mice have 
been created, which carry a single histidine to arginine amino acid exchange in the α1, α2, 
α3 or α5-GABAAR subunit. These mutations render the receptor insensitive to 
benzodiazepines (Rudolph and Mohler, 2006, Knabl et al., 2008). Using this tool, it has 
General Introduction 
24 
 
become clear that different GABAAR subunits contribute to distinct effects of BDZ. Sparing 
the α1-containing GABAARs, which are expressed preferentially in the brain cortex, the 
classical BDZ diazepam (DZP) produces profound analgesia without any sedation (Knabl et 
al., 2008, Ralvenius et al., 2015). Moreover, α2 and α3-GABAARs have been shown to be the 
most relevant subtypes for BDZ-mediated antihyperalgesia after systemic DZP 
administration (Figure 5A) (Ralvenius et al., 2015). This characteristic feature matches well 
with the expression pattern of different  subunits in the superficial spinal dorsal horn (Figure 
5B-E) (Bohlhalter et al., 1996, Paul et al., 2012). Therefore, sparing BDZ activity at α1, the 
antihyperalgesic effects of BDZs can be studied in absence of confounding sedative effects.  
 
Figure 5. Contribution to antihyperalgesia and distribution of the BDZ-sensitive α subunits of 
the GABAARs in the dorsal spinal cord. (A) Contribution of the different α subunits to spinal 
antihyperalgesia in comparison with other behavioral BDZ-mediated effects. (B-E) Expression pattern 
of α1 (B), α2 (C), α3 (D) and α5 (E). Scale bar 100 μm. Modified from Zeilhofer et al., 2015. 
Several subtype-selective compounds with reduced activity at α1GABAARs have been 
identified recently (Rudolph and Knoflach, 2011). For instance, NS11394, a compound that 
shows low intrinsic activity at α1GABAARs, exhibited antinociceptive activity at non-sedating 
doses in various inflammatory and neuropathic pain models (Mirza et al., 2008, Hofmann et 
al., 2012). L-838,417, which shows selectivity at α2, α3 and α5 and, was also efficacious 
against inflammatory and neuropathic pain. This compound lacks activity at α1-GABAARs, 
and it does not produce sedation (Knabl et al., 2008, Nickolls et al., 2011). HZ-166, a newly 
synthesized BDZ (Rivas et al., 2009) with better activity at α2/α1 than diazepam, exerts 
antihyperalgesic effects in different pain models with sedation only at high doses and no 
tolerance development (Di Lio et al., 2011, Paul et al., 2014). 
This evidence suggests that α2GABAAR-selective (α1-sparing) compounds might exert 
robust antihyperalgesia with low unwanted effects. Therefore, studying new compounds with 
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such a profile may provide new therapeutic approaches to restore inhibition in pathological 
pain states.  
Evidence for modulation of GABAARs by non-canonical BDZ-binding site 
ligands 
Although classical BDZs require the γ2 subunit for full potentiation, γ1 and γ3 containing 
GABAARs still exhibit some potentiation by BDZ-site ligands (Puia et al., 1991, McKernan et 
al., 1995, Khom et al., 2006, Baburin et al., 2008, Esmaeili et al., 2009). The substitution of 
phenylalanine at the position 77 to isoleucine in the γ2 subunit (γ2F77I) confers insensitivity 
to certain BDZs (Ogris et al., 2004). The generation of a mouse line carrying the γ2F77I 
mutation has led to a better understanding of benzodiazepine allosteric modulation on 
GABAARs (Cope et al., 2004, Ogris et al., 2004, Cope et al., 2005, Leppa et al., 2005, Wulff 
et al., 2007, Ramerstorfer et al., 2010, Leppa et al., 2011a, Leppa et al., 2011b). Indeed, 
there is evidence of a functional expression of BDZ-sensitive γ1GABAARs in γ2F77I 
histaminergic neurons, suggesting an in vivo role of non γ2-containing receptors on the 
modulation by BDZs (May et al., 2013). Additionally, evidence from our laboratory suggests 
that the BDZ-mediated spinal effect does not depend exclusively on the effect at γ2-
containing GABAARs. Indeed, the γ2GABAAR BDZ-antagonist flumazenil reduced analgesic 
effect of DZP only at high concentrations when spinally applied (Knabl et al., 2008), 
indicating that a non-classical benzodiazepine site was targeted. Moreover, a non-BDZ 
compound DMCM, which antagonizes γ2GABAARs but exerts agonistic effects at 
γ1GABAARs, produces antihyperalgesic actions in neuropathic and inflammatory pain 
models (Munro et al., 2008). Furthermore, while γ2 subunit is largely expressed throughout 
the brain, γ1 subunit is expressed in more restricted areas (Hortnagl et al., 2013). Therefore, 
compounds interacting selectively with γ1GABAARs might add another level of selectivity 
when one wants to target spinal GABAergic pain control. 
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2.	Aims	
The overall aim of this thesis was to explore opportunities for pharmacological restoration of 
compromised synaptic inhibition in the spinal dorsal horn in the context of chronic pain 
conditions. Two specific aims were defined which addressed GlyRs and GABAARs, 
respectively: 
Aim 1: Characterize the capacity of the non-anesthetic propofol derivative 2,6-DTBP as 
a GlyR modulator in vitro and assess the contribution of GlyR modulation to its 
analgesic effect in vivo. 
2,6-DTBP has previously been reported to be devoid of activity at GABAARs, to potentiate 
GlyR and to possess analgesic efficacy in vivo.  
Aim 2:  Characterize the modulatory effects of typical and atypical BDZs at canonical 
and non-canonical binding sites of the GABAARs. 
In this part of my project I pursued two research directions. (1) I compared the in vitro 
pharmacological profile of typical benzodiazepines (such as diazepam) with those of atypical 
benzodiazepines that either differed from classical compounds by their structure or showed 
reduced sedative properties than their classical counter parts. (2) Some previous findings of 
our group suggest that part of the analgesic effects of spinally applied benzodiazepines 
might occur through non-canonical benzodiazepine binding sites that might for example 
contain γ subunits different from γ2. There is some evidence that the γ1 subunit might be 
expressed in the spinal dorsal horn at higher levels than in the brain. I therefore tested the 
pharmacological profile of several benzodiazepine site ligands with analgesic efficacy on 
heterologously expressed GABAARs to compare their actions on γ2 and γ1 GABAARs. 
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ABSTRACT 
Diminished inhibitory neurotransmission in the superficial dorsal horn contributes to chronic 
pain. In inflammatory pain, this reduction occurs at least partially through a prostaglandin E2 
(PGE2) and protein kinase A (PKA)-dependent phosphorylation of a specific subtype of 
glycine receptors (GlyRs) containing 3 subunits. Here, we show that the non-anesthetic 
propofol derivative 2,6-di-tert-butylphenol (2,6-DTBP) reverses this inflammation-mediated 
dis-inhibition through a specific interaction with heteromeric GlyRs containing 
phosphorylated 3 subunits. Electrophysiological analyses of mutated receptors show that 
2,6-DTBP interacts with a conserved phenylalanine residue in the membrane-associated 
stretch between transmembrane regions 3 and 4 of the GlyR 3 subunit. In native spinal cord 
tissue, 2,6-DTBP modulated synaptic GlyR currents only after priming with PGE2, consistent 
with molecular modeling data that suggest that in heteromeric 3GlyRs this site is 
accessible to 2,6-DTBP only after PKA-dependent phosphorylation. In vivo, 2,6-DTBP 
reduced inflammatory hyperalgesia in a 3GlyR-dependent manner. Our data thus establish 
that potentiation of GlyR function is a promising strategy against chronic pain and that 2,6-
DTBP has a unique pharmacological profile favoring an interaction with GlyRs primed by 
peripheral inflammation.  
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INTRODUCTION 
Chronic pain states are associated with complex molecular and cellular changes in the 
peripheral and central nervous system (Basbaum et al., 2009; Zeilhofer et al., 2012; Luo et 
al., 2014). An increasing body of evidence indicates that diminished inhibitory GABAergic 
and glycinergic neurotransmission at the level of the spinal dorsal horn makes an important 
contribution to chronic pain states (Zeilhofer et al., 2012; Sandkühler 2009; Coull et al., 
2003). A variety of mechanisms have been identified which differentially contribute to 
diminished synaptic inhibition in various inflammatory and neuropathic pain states (Basbaum 
et al., 2009; Zeilhofer et al., 2012). In case of inflammatory pain, a reduction in glycinergic 
inhibition occurring through a PGE2- and PKA-dependent phosphorylation of a specific 
subtype of glycine receptors (i.e. those containing the 3 subunit, 3GlyR) has a major role 
(Harvey et al., 2004). Restoring activity of synaptic 3GlyR through positive allosteric 
modulators may therefore constitute a mechanism-based therapeutic approach against 
chronic inflammatory pain.  
Despite the importance of GlyRs in a variety of physiological processes, GlyR pharmacology 
is still poorly developed and only few GlyR modulators are available at present (Lynch 2009; 
Yévenes & Zelhofer, 2011a; Laube et al., 2002). Some of these compounds such as several 
propofol derivatives modulate GlyR at nanomolar or even subnanomolar concentrations (de 
la Roche et al., 2012; Eckle et al., 2012), but none of them are fully specific for GlyRs and 
many of them also modulate the function of other ion channels (Yévenes & Zelhofer, 2011a). 
This lack of specificity has hampered establishing causal links between molecular and 
therapeutic actions (Xiong et al., 2011; Xiong et al., 2012; Yang et al., 2008; Zhang et al., 
2013).  
Using molecular, electrophysiological and behavioral approaches, we explored the basis of 
GlyR allosteric modulation by the non-anesthetic propofol derivative 2,6-di-tert-butylphenol 
(2,6-DTBP). 2,6-DTBP potentiates currents through recombinant 1GlyRs (Ahrens et al., 
2004) but has negligible activity at GABAA receptors (GABAARs) (Ahrens et al., 2009; 
Krasowski et al., 2001). Here, we show that 2,6-DTBP is a positive 3GlyR allosteric 
modulator, which effectively restores the loss of 3GlyR-mediated inhibition in inflammatory 
pain states at least partially through a selective potentiation of phosphorylated GlyRs 
containing 3 and subunits. A specific phenylalanine residue in the 3 subunit appears 
critical for this potentiation. Thus, our results establish a novel mechanism for 
pharmacological intervention against inflammatory pain through phosphorylation-specific 
potentiation of spinal 3GlyR.  
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METHODS 
Reagents. 2,6-DTBP and PTX were obtained from Sigma-Aldrich. PGE2, bicuculline, 
strychnine, and H89-dihydrochloride were purchased from Tocris (Bristol, UK). D-APV and 
CNQX were obtained from ANAWA (Wangen, Switzerland).  2,6-DTBP and PGE2 were 
dissolved in DMSO at 100 µM and kept at -20°C.  
Electrophysiology on recombinant GlyRs. Recombinant GlyRs were transiently expressed 
in HEK293T cells (originally obtained from Atcc, LGC Standards GmbH, Wesel, Germany) 
using lipofectamine LTX (Invitrogen, Carlsbad, CA, USA). One µg of DNA / 35 mm dishes 
was used for transfection of 1and 3 subunits together with 0.5 g of an eGFP expression 
plasmid to allow identification of the transfected cells. In experiments on  heteromeric 
GlyRs, plasmids encoding  and  subunits were transfected at a ratio of 1:15. To confirm 
the expression of heteromeric GlyRs, picrotoxin (PTX)-sensitivity was routinely monitored 
(Lynch, 2009) (Figure S1). All recordings were made 18 - 36 hrs after transfection. The cDNA 
encoding the GlyRs has been described previously (Yévenes & Zeilhofer, 2011b) Mutations 
were inserted using the QuickChange site-directed mutagenesis kit (Agilent Technologies) or 
by an external supplier (Mutagenex, NJ, USA). Proper sequences of all constructs were 
confirmed by full-length sequencing.  
Glycine-evoked whole-cell currents were recorded at room temperature (20 - 24°C) at a 
holding potential of -60 mV using the patch-clamp technique. Patch electrodes (3 - 4 M) 
were pulled from borosilicate glass and filled with (in mM): 120 CsCl, 10 EGTA, 10 HEPES 
(pH 7.4), 4 MgCl2, 0.5 GTP and 2 ATP. The external solution contained (in mM) 150 NaCl, 10 
KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4), and 10 glucose. Recordings were performed 
with a HEKA EPC-7 amplifier and Patch Master v2.11 software (HEKA Elektronik, 
Lambrecht-Pfalz, Germany). Glycine was applied via a manually controlled gravity fed 
application system with an ID of 200 µm ID positioned 50 - 120 µm from the recorded cell. 
Glycine EC10 values for each GlyR studied were obtained experimentally after successive 
application of 1, 10, 30, 60, 100, 200, 500 and 1000 µM glycine (see also Table S2). The 
concentration-response curve parameters (EC50 and Hill coefficients, nh) were obtained from 
the curve fits of normalized concentration-response to the equation Igly = Imax[gly]nH/([gly]nH + 
[EC50]nH). The mean maximal current (Imax) was determined by applying 1 mM glycine. 2,6-
DTBP was first dissolved in DMSO (100%) at a concentration of 100 mM and subsequently 
diluted in several steps to the final concentration on the day of the experiment. Before use 
solutions were vigorously shaken for 60 min. Maximum DMSO concentration was 0.3%. 2,6-
DTBP was co-applied with glycine, without pre-application. Single channel recordings from 
transfected cells were done as described (19, 28). All recordings were performed in the cell-
attached configuration at 19 - 21°C with thick-walled borosilicate glass pipettes (final 
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resistance of 10 - 15 MΩ). The extracellular solution contained (mM): 20 Na-gluconate, 102.7 
NaCl, 2 KCl, 2 CaCl2, 1.2 MgCl2, 10 Hepes, 20 TEA-Cl, 15 sucrose, and 14 glucose, pH 7.4. 
The pipette solution was filled with the same extracellular solution but containing glycine (100 
- 150 µM) or glycine plus 2,6-DTBP (10 µM). Single channel currents were recorded with an 
RK-400 patch-clamp amplifier (Bio-Logic) at a pipette potential of +60 mV. Recordings were 
pre-filtered at 10 kHz and were digitized to a computer using a Digidata 1400 (Molecular 
Devices) and pClamp 10 (Axon Instruments). 
Molecular modeling and docking. Because most of the structural data available on GlyRs 
do not include the TM3-TM4 intracellular domain, we modeled the 3 subunit as previously 
described for 1GlyR (Burgos et al., 2015) using the ab initio technique with QUARK (Xu & 
Zhang, 2012). The full 3GlyR subunit was created by homology modeling using GluCl 
[PDB: 2RIF] (Hibbs & Gouaux, 2011) as template in Modeller 9v13 (Eswar et al., 2006). 
Additional refinement was performed using the 1GlyR-GLIC structure (Moraga-Cid et al., 
2015). The final model was obtained after energy minimization with a conjugate gradient 
protocol in the software MacroModel (version 9.9, Schrödinger, LLC, New York, NY, 2012). 
The resulting helical conformation of the C-terminal region of the TM3-TM4 intracellular 
domain (MA-stretch) of 3GlyR was similar to the recently resolved structure for the 5-HT3 
receptor (Hassaine et al., 2014) and to the proposed TM3-TM4 intracellular domain of the 
1GlyR subunit (Burgos et al., 2015). Docking protein-ligand was performed using the model 
of 3 subunit and the 2,6-DTBP structure available in the ZINC database [ID: 
ZINC01681254] (Irwin et al., 2012). An initial complex was created with Glide (version 5.9, 
Schrödinger, LLC, New York, NY, 2013) using a receptor grid centered on residue F388 of 
3GlyR. Analysis of the interface by the same software including structural and energetic 
parameters generated a docking score (Friesner et al., 2006). Additionally, a second energy 
calculation MM-GBSA was performed using Prime (version 3.2, Schrödinger, LLC, New 
York, NY, 2013) to predict a theoretical Gbind. Taken together, the docking score and Gbind 
improved the description of the interaction between 3GlyR and 2,6-DTBP. The   subunit 
was modeled using the 1GlyR model (Burgos et al., 2015) and interfaces 3-3 and 3- 
were constructed based on the 1GlyR pentamer [PDB: 2M6B] (Mowrey et al., 2013). The 
3GlyR F388 mutant was created using BioLuminate (version 1.1, Schrödinger, LLC, New 
York, NY, 2013) and consequent dockings were performed under the same conditions 
described above. All images were created using PyMol (version 1.5, DeLano Scientific LLC). 
In situ proximity ligation assay (in situ PLA). PGE2-induced phosphorylation of the 3 
GlyR subunit was analyzed using the in situ PLA (Leuchowius et al., 2010). cDNAs of GlyR 
3 and EP2, or GlyR 3(S246A) and EP2 were transfected into HEK293T cells grown on 
poly-lysine-coated coverslips using the PEI (polyethylenimine) method. Two days after 
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transfection, cells were incubated in 1 M PGE2 for 30 min. After fixation in 4% PFA for 30 
min cells were permeabilized in 0.2% Triton/PBS. Phosphorylation of 3GlyR was tested with 
the in situ PLA using antibodies directed against 3GlyR (1:50, Millipore cat. # AB15014) and 
phosphoserine (1:5, Millipore cat. #05-1000X). The cells were incubated with the primary 
antibodies overnight and processed for in situ PLA using the Duolink kit (Sigma-Aldrich) as 
described previously (Zemoura & Benke, 2014). Images (as z-stack with a 0.8 m z-interval) 
were taken with a Zeiss 510 Meta confocal laser scanning microscope using a Zeiss 100x 
plan-fluar objective (N.A. = 1.4). Quantification of in situ PLA signals was done by counting 
individual PLA fluorescence spots using ImageJ (NIH). The optical sections of each image 
stack were summed into one image, median filtered (r = 1.0 pixels) and subjected to 
automated spot detection. The number of spots was then normalized to the cell area. 
RT PCR. Six lumbar spinal cords were rapidly removed from euthanized adult wild-type and 
GlyR3-/- mice. mRNA was transcribed into cDNA using the QuantiTect Reverse 
Transcription Kit (Qiagen no.205311). Expression levels of GlyR 1 and  subunits relative to 
-actin were determined using commercially available detection assays (Integrated DNA 
Technologies, Leuven, Belgium, catalog number Mm.PT.58.9052470 for glra1, 
Mm.PT.58.29236025 for glrb, and Mm.PT.58.33257376.gs for actb). 
Recordings in spinal cord slices. Transverse spinal cord slices were prepared from 2 to 3-
week-old vGAT::ChR2-eYFP mice (Zhao et al., 2011) and GlyR3 deficient (GlyR3-/-) mice 
(Harvey et al., 2004) of either sex. Slices (400 m thick) were kept in oxygenated (95% 
O2/5% CO2) artificial cerebrospinal fluid (aCSF) containing (in mM): 120 NaCl, 5 HEPES, 26 
NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 2 CaCl2, 1 MgCl2, and 10 glucose (pH 7.35) at 35°C for 1 
hr. Slices were then transferred to the recording chamber continuously perfused with 
oxygenated aCSF at a flow rate of 1.5 - 2.0 ml/min. Superficial dorsal horn neurons were 
visually identified using infrared gradient contrast equipment. Recordings in neurons 
obtained from vGAT::ChR2 mice were made from excitatory neurons identified by the 
absence of a light-induced photocurrent. Recordings in neurons from GlyR3-/- mice were 
made from randomly chosen lamina II neurons. Whole-cell patch-clamp recordings were 
made at room temperature at a holding potential of -60 mV using a HEKA EPC-10 amplifier 
and Patch Master v2.11 software (HEKA Elektronik, Lambrecht-Pfalz, Germany). Patch 
pipettes (3.5 - 4.5 M were filled with internal solution containing: (in mM) 120 CsCl, 10 
EGTA, 4 MgCl2, 0.5 GTP, 2 ATP, and 10 HEPES (pH 7.30 adjusted with CsOH). QX-314 (5 
mM) was added to block voltage-activated Na+ currents in the recorded cell. Once the whole-
cell mode was established, the cell was allowed to stabilize for 2 - 5 min. Light-evoked 
inhibitory post-synaptic currents (IPSCs) were elicited by whole-field blue light (473 nm) 
illumination (4 ms duration) at a frequency of 0.1 Hz. Glycinergic or GABAergic light-evoked 
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IPSCs were isolated using bicuculline (10 M) or strychnine (1 M), respectively. In GlyR3-/- 
mice, glycinergic IPSCs were evoked by electrical field stimulation at a frequency of 0.1 Hz 
(100 μs, 3 - 30 V) using a glass electrode (5 – 7 M filled with standard extracellular 
solution and placed about 50 μm from the recorded neuron (6). Gly-IPSCs were isolated 
using CNQX (5 μM), D-APV (50 μM) and bicuculline (10 μM). After 3 - 5 min of baseline 
recording, 2,6-DTBP (100 M) or PGE2 (1 M) were added to the bath solution for 8 - 10 min. 
To examine the role of PKA-dependent phosphorylation, slices were continuously superfused 
with H89 (5 M). At the end of each recording, strychnine (1 M) or bicuculline (10 M) were 
added to confirm the glycinergic or GABAergic nature of the recorded IPSCs.  
Animals. Breeding pairs of GlyR3−/− mice (Harvey et al., 2004)(6) were kindly provided by 
Dr. Robert J. Harvey, Dr. Ulrike Müller and Dr. Heinrich Betz (all the Max-Planck-Institute for 
Brain Research, Max-von-Laue Strasse 4, D-60438 Frankfurt, Germany). vGAT::ChR2-eYFP 
mice (29) were provided by Dr. Guoping Feng, McGovern Institute for Brain Research at 
MIT, 43 Vassar Street, Cambridge, MA 02139. GlyR3−/− mice and vGAT::ChR2-eYFP BAC 
transgenic mice were maintained on a C57BL/6 background. All mice were group housed 
with standard 12-hr light/dark cycle and food and water available ad libitum.  
Behavioral tests Antihyperalgesic properties of 2,6-DTBP (90 mg/kg i.p.) were studied in 7 - 
12 week old mice subjected to the zymosan A and Complete Freund’s Adjuvant (CFA) 
models of inflammatory hyperalgesia (Harvey et al., 2004; Meller & Gebhart, 1997). Mice 
were injected subcutaneously with either zymosan A (0.06 mg in 20 l saline) or CFA (1:2 
diluted in saline) into the plantar side of the left hind paw. To study the effects of 2,6-DTBP 
on neuropathic pain, mice were subjected to the chronic constriction injury (CCI, (Bennet & 
Xie, 1988)). In brief, three loose (5-0 silk) ligatures were put around the left sciatic nerve 
proximal to the trifurcation. Mice that showed signs of paralysis or did not develop significant 
hypersensitivity were excluded from subsequent experiments. Mechanical and thermal 
nociceptive sensitivities were determined using electronic von Frey filaments and the plantar 
test, respectively. 2,6-DTBP was dispersed in saline/0.05% TWEEN20 (vehicle), sonicated 
on ice and injected intraperitoneally (i.p.) (see also (Tibbs et al., 2013)). Sensitivities of the 
ipsilateral (inflamed or nerve-injured) paw and the contralateral control paw were measured 
alternately and at least four measurements were taken per mouse for all time points. 
Antihyperalgesia was quantified for the time interval of 30 - 60 (for zymosan A model and 
CCI) or 60 – 90 min (for CFA) post-drug injection when the drug effect was maximal, and 
expressed as percent maximum possible analgesic effect (MPE). MPE = (Rpost-drug - Rpre- 
drug)/(Rbaseline - Rpre-drug) x 100, where R is the average response latency or threshold under 
baseline condition (Rbaseline), after induction of inflammation but before drug injection (Rpre-
drug), and after drug injection (Rpost-drug). Accelerating rotarod performance (from 4 to 40 r.p.m.) 
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of wild-type mice was measured after 60 min of the administration of 2,6-DTBP or vehicle. 
Each mouse was tested three times. Mice were trained with 2 different training sessions on 2 
consecutive days before testing. The locomotor activity assays were performed during the 
light phase of the day-night cycle. The animals were placed in individual circular enclosures 
(diameter 20 cm) equipped with 4 photocells. The locomotor activity was expressed as the 
total number of photocell interruptions recorded in a period of 6 hrs immediately after drug 
administration. The horizontal wire test (Bonetti et al., 1982) was performed to assess 
potential muscle relaxation. Mice were placed forepaws‐first onto a 15 cm metal wire and 
scored according to whether or not they were able to grasp the wire with their hindpaws or 
not. Acute pain was measured in the so called pin-prick test using an injection needle applied 
to the plantar surface of the hindpaw without breaking the skin. The number of paw 
withdrawals out of three trials was calculated as a percent for each time point. The 
experimenter was blind to mouse genotype and drug treatment. Special care was taken to 
ensure equal numbers of age-matched male and female mice in all behavioral experiments. 
Statistics. All data are displayed as mean ± standard error of means (SEM). Statistical 
comparisons were made with 2-tailed paired or unpaired t-tests or with ANOVA or repeated 
measures ANOVA followed by appropriate post hoc tests. p values < 0.05 were considered 
statistical significant. 
Study approval. Permission for the animal experiments was obtained from the 
Tierversuchskommission of the canton of Zurich, Zurich, Switzerland (license numbers 
135/2009 and 126/2012). 
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RESULTS 
Conformation-specific potentiation of recombinant 3GlyR by 2,6-DTBP  
We first assessed the effects of 2,6-DTBP on glycine-evoked currents through recombinant 
GlyRs expressed in HEK293T cells. Homopentameric GlyRs composed of 3 subunits 
(3GlyR) were strongly potentiated by micromolar concentrations of 2,6-DTBP (Figure 1A-B). 
The efficacy of potentiation by 2,6-DTBP (determined at a 2,6-DTBP concentration of 100 µM 
and at the EC10 of glycine) was higher for 3GlyRs than for 1GlyRs (211 ± 30% versus 115 
± 19%, p < 0.05, n = 6, unpaired t-test). We next assessed the modulation of heteromeric 
GlyRs (as these receptors constitute most GlyRs at postsynaptic sites). The efficient 
expression of heteromeric GlyRs containing both  and  subunits was confirmed by their 
relative insensitivity to picrotoxin (PTX), which blocks homomeric GlyRs with higher potency 
than  heteromeric receptors (Figure S1). Compared to homomeric GlyRs, potentiation of 
heteromeric 3 or1 GlyRs was significantly weaker (20 ± 10% and 30 ± 6% for 3 and 
1GlyRs, respectively, Figure 1A-C). We then evaluated the biophysical mechanisms 
underlying the allosteric modulation by 2,6-DTBP of 3GlyRs. Whole-cell recordings showed 
that 2,6-DTBP caused a leftward shift in the glycine concentration-response curve of 3GlyR. 
EC50 values were 206 ± 1.0 M and EC50 = 76 ± 2.3 M, under control conditions and in the 
presence of 100 M 2,6-DTBP, respectively, p < 0.001, unpaired t-test (Figure 1D), 
suggesting an increase in the apparent affinity of the receptor for its agonist. 2,6-DTBP did 
not affect the maximal current amplitude elicited by 1 mM glycine (5.0 ± 1.0 nA versus 4.8 ± 
1.1 nA, in the presence and absence of 100 µM 2,6-DTBP, respectively). Single channel 
recordings in the cell-attached configuration (Marabelli et al., 2013) showed that 2,6-DTBP 
significantly increases the ion channel open probability (control nPo = 0.20 ± 0.02 versus 2,6-
DTBP nPo = 0.58 ± 0.10, paired t-test, p < 0.01, Figure 1E,F, Table S1) without apparent 
changes in the main conductance levels (control = 91.0 ± 1.20 pS versus 2,6-DTBP  = 
90.1 ± 0.92 pS, paired t-test, Figure 1E,F, Table S1).  
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Figure 1. Modulation of recombinant GlyRs by 2,6-DTBP in HEK293T cells. (A) Example whole-
cell current traces evoked by glycine (EC10) in the absence or presence of 2,6-DTBP (100 µM) in 
homomeric 3 or 1GlyRs, and in heteromeric 3 or 1GlyRs. (B) Concentration-response curves 
of 2,6-DTBP obtained with an EC10 of glycine in homomeric 3 or 1GlyRs, and in heteromeric 3 or 
1GlyRs. (C) Heteromeric 3/ and 1/ GlyRs are significantly less susceptible to modulation by 
2,6-DTBP than homomeric 1 and 3GlyRs. **, p < 0.01, unpaired t-test. (D) Concentration-response 
curves of glycine in homomeric 3GlyR in the absence or in the presence of 2,6-DTBP (100 µM, red). 
(E) Single channel current traces recorded from membranes expressing 3GlyRs in the presence and 
the absence of 2,6-DTBP (10 µM). (F) 2,6-DTBP increases ion channel open probability (nPo) but not 
single channel main conductance. **, p < 0.01, paired t-test. Data are mean ± SEM from 6 - 10 cells 
(B-D) or 6 patches per group (F).  
 
In order to explore the molecular determinants of 3GlyR modulation by 2,6-DTBP, we first 
focused on molecular sites in 1GlyR and 3GlyR involved in the modulation by propofol, the 
parent compound of 2,6-DTBP. Previous analyses of structure activity relationships have 
identified S267 in TM2, A288 in TM3 and F380 in the interface between the intracellular 
region and the TM4 domain as critical for the modulation of 1GlyR by propofol (Ahrens et 
al., 2008; Moraga-Cid et al., 2011; Lynagh & Laube, 2014). All three residues are conserved 
between 1GlyR and 3GlyR. Other studies have however found that mutation of two of 
these residues (S267 and A288) also severely interferes with GlyR function itself Mihic et al., 
1997; Findlay et al., 2003). By contrast, mutation of F380 diminished propofol sensitivity 
without altering ion channel gating and conductance (Moraga-Cid et al., 2011). We therefore 
examined whether the mutation of phenylalanine to alanine in position 388 (F388A) would 
affect the sensitivity of 3GlyR to 2,6-DTBP. Whole-cell recordings revealed that the F388A 
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mutation did not change the sensitivity of homomeric 3GlyR to glycine (Figure 2A), but 
significantly impaired sensitivity to 2,6-DTBP. At 100 M, 2,6-DTBP potentiated wild-type 
3GlyR by 164 ± 20% (n = 12), whereas potentiation of F388A 3GlyR only reached 10 ± 
9.0% (n = 10) (Figure 2B,C). To gain additional molecular insight, we analyzed the effects of 
2,6-DTBP in single channel recordings of 3GlyR carrying the F388A mutation. 2,6-DTBP 
(10 M) did not significantly modify activity of F388A mutant ion channels (control nPo= 
0.18±0.05 versus 2,6-DTBP nPo = 0.19 ± 0.04, paired t-test), confirming the low sensitivity of 
the mutated receptor to modulation by 2,6-DTBP (wild-type = 192.8 ± 32.6% of nPo increase 
above control versus F388A = 5.7 ± 15.6%, unpaired t-test, p < 0.001, Figure 2D-F, Table 
S1). Additional analyses revealed that wild-type and F388A mutant GlyR3 exhibited similar 
conductance levels (wild-type = 91.0 ± 1.20 pS versus F388A  = 88.2 ± 1.82 pS, p = 0.44, 
unpaired t-test). These results confirm that the F388A mutation diminished the sensitivity of 
3GlyRs to 2,6-DTBP without altering the ion channel function. 
 
Figure 2. A molecular site for the actions of 2,6-DTBP on 3GlyRs. (A) Concentration-response 
curves of glycine in wild-type and (F388A) point mutated 3GlyRs. (B) Traces of glycine-activated 
whole-cell currents recorded from cells expressing wild-type or (F388A) point mutated 3GlyRs in the 
absence or presence of 2,6-DTBP (100 µM). (C) Concentration-response curves of 2,6-DTBP for wild-
type and (F388A) point mutated 3GlyRs. (D) Examples of single channel recordings from 
membranes expressing point mutated (F388A) 3GlyRs in the presence or absence of 2,6-DTBP. (E) 
Ion channel nPo of the (F388A)3GlyR in the absence or presence of 2,6-DTBP (10 µM). (F) Percent 
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change of nPo following the application of 2,6-DTBP in wild-type and (F388A) point mutated 3GlyRs. 
***, p < 0.001, unpaired t-test. All data are mean ± SEM from 6 - 9 cells per group. 
 
A molecular site for the actions of 2,6-DTBP on 3GlyR 
The F388 residue required for modulation by 2,6-DTBP lies within the so called membrane 
associated (MA) stretch of the channel immediately upstream of the transmembrane region 4 
(Carland et al., 2009). This site is close to a consensus site for PKA-dependent 
phosphorylation of GlyR3 (serine 346) that has been previously implicated in inflammation-
induced inhibition of synaptic GlyR currents in the superficial spinal dorsal horn (Harvey et 
al., 2004) (Figure 3A, note that the GlyR1 subunit lacks this consensus site). In order to 
provide direct evidence for a PKA-dependent phosphorylation S346 in GlyR3, we made use 
of the in situ proximity ligation assay (in situ PLA, (Leuchowius et al., 2010)). Incubation of 
HEK293T cells transiently transfected with wild-type GlyR3 subunits and EP2 receptors led 
to a significant increase in the phosphorylation-dependent PLA signal after exposure to PGE2 
(1 µM). This increase was absent in point mutated GlyR3(S346A) (Figure 3B,C). To explore 
a potential interaction of phosphorylation at S346 with 3GlyR modulation by 2,6-DTBP, we 
investigated the impact of S346 phosphorylation on the 3GlyR function and modulation and 
tested two point mutated receptors that mimic the phosphorylated (S346E) and non-
phosphorylated (S346A) state. Electrophysiological recordings revealed that the 
phosphorylation state did not affect the sensitivity of homomeric or heteromeric 3GlyRs to 
their natural agonist glycine (Figure S2, Table S2). Likewise, homomeric GlyRs composed 
GlyR3(S346A) or GlyR3(S346E) did not differ much in their sensitivities to 2,6-DTBP (142 
± 23% in S346A versus 190 ± 42% in S346E, 100 M 2,6-DTBP, Figure 3D-F).  However, 
heteromeric GlyRs containing the phosphomimicking S346E mutation were significantly more 
sensitive to 2,6-DTBP than those containing the S346A mutation (S346A: 10 ± 8% versus 
S346E: 112 ± 31%, 100 M 2,6-DTBP, p < 0.01, unpaired t-test). These results demonstrate 
that the heteromeric phosphorylated 3GlyRs are more sensitive to modulation by 2,6-
DTBP, indicating a conformation-selective modulation of 3GlyRs. We then examined 
whether the mutation of F388 could affect the 2,6-DTBP sensitivity of phosphorylated 
3GlyR. To this end, we studied double point mutated 3GlyRs containing both the S346E 
and the F388A mutation. The F388A mutation significantly attenuated the potentiation of 
homomeric 3(S346E)GlyRs and heteromeric 3(S346E)GlyRs (Figure 3G). These data 
indicate that the F388 residue is critical for the potentiation of both homomeric 3 and 
heteromeric (phosphorylated) 3GlyRs.  
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Given the key role of F388 in the actions of 2,6-DTBP on 3GlyR, we next asked whether 
this residue could be a critical part of an acceptor site for 2,6-DTBP. To this end, we 
developed a model of 3GlyR based on the crystal structures of GluCl and GLIC-GlyR 
(Hibbs & Gouaux, 2011). The results of this modeling were not only consistent with F388 
being located in the MA-stretch close to transmembrane segment 4 (Figure 3H) but also 
provided insights into the molecular composition of the putative acceptor site for 2,6-DTBP. 
Three residues (F388, M384 and P381) appeared as particular relevant for hydrophobic 
interactions of 2,6-DTBP with 3GlyRs. The charged residues D382 and R385 complement 
the binding area. Molecular docking analyses revealed a favorable theoretical energy of 
interaction with this putative acceptor site (Gbind = -42.09 kcal/mol, docking score = -2.133). 
The energy of interaction and the docking scores of 2,6-DTBP and of other propofol analogs 
with this molecular site correlate well with the functional modulation of wild-type 3GlyRs 
(Table S3). Interestingly, our modeling data suggest that the introduction of the F388A 
mutation causes a significant decrease in these parameters (Gbind = -29.51 kcal/mol, 
docking score = -0.507), suggesting a direct relationship between the degree of potentiation 
of 3GlyR by 2,6-DTBP and the energy of interaction. Additional molecular modeling and 
simulations suggest that the  GlyR subunit also displayed a lower energy of interaction with 
2,6-DTBP (Gbind = -27.99 kcal/mol, docking score, 0.194), possibly because of the presence 
of an isoleucine at position 388 (i.e. I443 in the  subunit) and a poor structural homology 
with the subunits in these particular regions (Figure S3). Overall, these results identified 
F388 as a pivotal residue for the actions of 2,6-DTBP on 3GlyR and suggest the presence 
of a 2,6-DTBP acceptor site in the MA-stretch of 3 that is not present within the  subunit.  
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Figure 3. Influence of S346 phosphomutations in 3GlyR on allosteric modulation by 2,6-DTBP. 
(A) Localization of the S346 residue in the primary sequence of the mouse GlyR3 subunit, 
corresponding sequence in GlyR1 subunit, and schematic diagram illustrating this site in the 3GlyR 
topology. (B) Proximity ligation assay (PLA) demonstrating phosphorylation of 3GlyR by PGE2 (1 µM) 
in HEK293T cells transfected with EP2 receptor and wild-type or 3(S346A)GlyR subunit plasmids. 
Top: 3GlyR immunofluorescence, bottom: PLA signal. Scale bar, 5 µm. (C) PGE2 significantly 
increased PLA signals in HEK293T cells transfected with wild-type but not with (S346A)3GlyR 
subunits. ***, p<0.001, ANOVA followed by Bonferroni post hoc test, F(2,141)=49.84, p<0.001, PGE2 
in wild-type 3GlyR transfected cells versus both other conditions. (D) Example traces of glycine-
activated currents in 3(S346A) or 3(S346E)GlyRs in the absence and presence of 2,6-DTBP 
(100 µM). (E) Concentration-response curves to 2,6-DTBP in homomeric 3 (left) and heteromeric 
3GlyRs (right) containing S346E or S346A mutations. (F) The phosphomimicking S346E mutation 
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restored 2,6-DTBP sensitivity of 3GlyRs but had little effect on that of homomeric 3GlyRs. **, 
p<0.01, unpaired t-test. (G) The F388A point mutation in 3GlyRs abolished 2,6-DTBP sensitivity. 
Introducing the S346E mutation did not restore 2,6-DTBP sensitivity in homomeric 3(F388A)GlyRs or 
heteromeric 3(F388A)GlyRs. **, p<0.01, ***, p<0.001, ANOVA followed by Bonferroni post hoc test, 
F(3,35)=20.7 (left) and F(2,16)=8.81 (right). (H) Structural model of 3GlyR. Left: location of the F388 
residue (red) and of 2,6-DTBP (yellow sphere) in a homopentameric 3GlyR. Other relevant residues 
are shown in magenta (P381 and M384) and blue (D382 and R385). Top right: view from the middle of 
the plasma membrane on the putative acceptor sites with 2,6-DTBP bound (in yellow spheres) within a 
pentameric complex. Bottom, right: detailed view of the putative acceptor site of 2,6-DTBP. The 
hydrophobic interaction supported by F388 is highlighted in red. 
Modulation of Gly-IPSCs by 2,6-DTBP in superficial dorsal horn neurons 
We next characterized the effects of 2,6-DTBP on native GlyRs in excitatory lamina II dorsal 
horn neurons, i.e. at a site that serves a pivotal role in pain control and which expresses a 
high density of 3GlyR (Harvey et al., 2004). To this end, we prepared lumbar spinal cord 
slices from vGAT::ChR2 BAC transgenic mice (Zhao et al., 2011), which permit selective 
activation of inhibitory neurons through short pulses of blue light (Foster et al., 2015). In 
slices taken from these mice, excitatory neurons can be readily identified by the absence of a 
photocurrent (for details see Methods and (Foster et al., 2015)). Of a total of 256 lamina II 
dorsal horn neurons, 121 were photocurrent negative and hence presumably excitatory. 
Wide field stimulation with blue light elicited inhibitory postsynaptic current (IPSC) responses 
in all these cells. Bicuculline  (10 µM) or strychnine (1 µM) were used to isolate glycinergic or 
GABAergic IPSCs (Gly-IPSCs or GABA-IPSCs), respectively. We then analyzed the effect of 
2,6-DTBP (100 µM) on the amplitudes and decay time constants of light-evoked Gly-IPSCs 
and GABA-IPSCs (Figure 4). As expected from the experiments in recombinant GlyRs, 2,6-
DTBP had no significant effect on Gly-IPSCs under basal conditions. Gly-IPSC amplitudes 
slightly decreased by -8.6 ± 3.1% of control values (n = 8, p = 0.09, paired t-test), while rise 
time and decay time slightly increased by 13 ± 9% and 14 ± 9% (p = 0.50 and p = 0.17, 
paired t-test) (Figure 4A-C). Likewise, light-evoked GABA-IPSCs were not significantly 
affected (-6.1 ± 7.3%; p = 0.57, and 1.1 ± 9.6%; p = 0.92, for amplitudes and decay time 
constants, n = 6) (Figure 4D-F). It is likely that most of the receptors underlying these 
synaptic currents were heteromeric receptors containing 1 and/or 3 subunits together with 
 subunits (Harvey et al., 2004). To address a potential effect on extrasynaptic receptors, we 
analyzed whether 2,6-DTBP would modulate tonic GlyR currents. In agreement with previous 
results (Mitchell et al., 2007), these experiments revealed the presence of small amplitude 
tonic currents (Itonic = 3.2 ± 1.0 pA) in only a small fraction of the superficial dorsal horn 
neurons (4/14). These tonic currents were not significantly changed by 100 M 2,6-DTBP 
(4.6 ± 7.6% of control amplitudes, p = 0.56, paired t-test, Figure S4). The present results 
indicate that, in slices taken from naïve mice, neither synaptic nor extrasynaptic GlyRs were 
susceptible to significant modulation by 2,6-DTBP.  
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Figure 4. 2,6-DTBP has no significant effects on evoked glycinergic and GABAergic 
neurotransmission in naïve superficial dorsal horn neurons. (A-C) Effects of 2,6-DTBP (100 µM) 
on amplitudes (mean ± SEM) (A) or decay time constants (B) of light-evoked Gly-IPSCs. Inset, 
example glycinergic IPSC traces averaged from 10 consecutive current traces (A) or scales traces (B). 
Grey, control condition, red 2,6-DTBP. (C) Paired t-test, p = 0.12 and p = 0.28, for amplitudes and 
decay time constants, respectively, n = 6. (D-F) Same as (A-C) but GABA-IPSCs. (F) Paired t-test, p = 
0.47 and p = 0.37 for amplitudes and decay time constants, respectively, n = 6. 
 
Since our data obtained in recombinant GlyRs have shown that the phosphorylation of the 3 
subunit at S346 increases the sensitivity of 3 GlyRs to 2,6-DTBP (compare Figure 3D-F), 
we hypothesized that glycinergic synapses containing the 3 subunit might be more sensitive 
to 2,6-DTBP under inflammatory conditions, i.e. in a phosphorylated state. We therefore 
assessed the effects of 2,6-DTBP on Gly-IPSCs after preconditioning of the slices with PGE2 
(Figure 5). Superfusion of the slices with PGE2 (1 µM) significantly reduced the amplitude of 
the Gly-IPSC (-35 ± 5% of control amplitudes, p < 0.001, n = 12, paired t-test) but did not 
change their rise or decay time kinetics (rise time: -0.2 ± 8% change of control, decay time: 6 
± 7% change of control, p = 0.99 and p = 0.23, paired t-test, n = 12) (Figure 5A,D). 
Subsequent application of 2,6-DTBP significantly increased the decay time constant of Gly-
IPSCs by 54 ± 11% (p < 0.001, n = 12, paired t-test) but had no significant effect on the 
amplitudes (+8 ± 10% of amplitudes during PGE2, p = 0.37, n = 12, paired t-test) (Figure 
5A,D). Analyses of the charge transfer occurring during Gly-IPSCs revealed that the 
prolongation of the decay time by 2,6-DTBP fully compensated for the reduction of Gly-IPSC 
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amplitudes by PGE2. The change in IPSC charge transfer during PGE2 relative to control was 
-33 ± 5% (p < 0.001, paired t-test, n = 12). In the additional presence of 2,6-DTBP, the total 
charge transfer increased to 108 ± 18% of control (n =12). Superfusion of vehicle (0.1% 
DMSO) had no effect on either amplitudes or decay kinetics of Gly-IPSCs (8.5 ± 7.5%, p = 
0.27, and 19 ± 12%, p = 0.24, for amplitudes and decay time constants, respectively, n = 7). 
To verify the critical role of PKA-dependent phosphorylation in the priming of spinal cord 
slices by PGE2, we pre-incubated slices with the PKA inhibitor H89 (5 µM) (Figure 5B,D). 
Under these conditions, PGE2 did no longer sensitize GlyR to the potentiating actions of 2,6-
DTBP (change in decay time constant by 2,6-DTBP: -1.8 ± 10.2%, p = 0.73, paired t-test, n = 
7). To further prove that GlyR3 was the relevant target of PKA-dependent phosphorylation, 
we performed experiments in slices taken from GlyR3-/- mice (Figure 5C,D). Before that, we 
tested whether the expression of GlyR1 or GlyR subunits changed following the loss of 
GlyR3 expression. Real time PCR analyses of lumber spinal cord dorsal horn tissue from 
wild-type and GlyR3-/- mice did not reveal significant changes. mRNA copy numbers relative 
to -actin were 0.037 ± 0.017 versus 0.047 ± 0.012 for the 1 subunit (glra1; n = 6 for both 
groups, p = 0.28 unpaired t-test), and 0.021 ± 0.009 versus 0.021 ± 0.004 for the  subunit 
(glrb; n = 6 for both groups, P = 0.99 unpaired t-test) in wild-type versus GlyR3-/- mice, 
respectively.  
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Figure 5. Pretreatment with PGE2 renders synaptic 3GlyRs susceptible to modulation by 2,6-
DTBP. (A) Normalized amplitudes (mean ± SEM) (top panel) and decay time constants (bottom panel) 
of light-evoked Gly-IPSC traces versus time, before and during the application of PGE2 (1 µM) and in 
the additional presence of 2,6-DTBP (100 µM). Insets are example traces averaged from 10 
consecutive stimulations under the three conditions (n = 12). (B) Same as (A) but preincubation with 
H-89 (5 µM) to prevent phosphorylation of GlyRs by PGE2 (n = 7). (C) Same as (A) but experiments 
done in slices taken from GlyR3-/- mice. In these experiments, Gly-IPSCs were evoked by electrical 
field stimulation, n = 12. (D) Left panel: PGE2 reduced Gly-IPSC amplitudes in control slices but not in 
H89-treated slices or in slices from GlyR3-/- mice, while 2,6-DTBP had no significant effects on Gly-
IPSC amplitudes in either condition. ** p < 0.01 significant versus control. ANOVA followed by 
Bonferroni post hoc test. F(2,35) = 8.58, F(2,18) = 1.76, and F(2,30) = 0.12 for Gly-IPSC amplitudes 
shown in (A), (B), and (C), respectively. Right panel: 2,6-DTBP significantly prolonged Gly-IPSC decay 
time courses in PGE2-treated wild-type slices, but not in slices pre-treated with H89, or in slices 
prepared from GlyR3-/- mice. ANOVA followed by Bonferroni post hoc test. +++, p < 0.001 significant 
versus PGE2, *** p < 0.001 significant versus control. F(2,35) = 15.66, F(2,18) = 0.20, and F(2,30) = 
0.62 for experiments shown in (A), (B), and (C), respectively. n = 7 – 12 cells per group. All scale bars, 
50 ms, 400 pA. 
These data are consistent with unchanged expression and distribution of the GlyR1 protein 
in the dorsal horn of GlyR3-/- mice reported previously (Figure S1 in ref. 6). Since the 
vGAT::ChR2 transgene had not been crossed into GlyR3-/- mice, we evoked glycinergic 
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IPSCs in these experiments by electrical field stimulation rather than through optogenetic 
stimulation. In GlyR3-/- mice, PGE2 failed to render Gly-IPSCs susceptible to modulation by 
2,6-DTBP (change in decay time constant induced by 2,6-DTBP: 1.2 ± 8.1% change of 
control, p = 0.74, paired t-test, n = 12). Because GlyR3-/- the mice lacked vGAT::ChR2 
transgene, the presence or absence of photocurrents could not be used to distinguish 
between inhibitory and excitatory neurons. Nevertheless, we expect that at least half of these 
recordings were made from excitatory neurons (see also ref (Todd & Spike, 1993)). Taken 
together, both PKA inhibition and absence of GlyR3 prevented the priming effect of PGE2 
on GlyRs supporting that 2,6-DTBP potentiates synaptic GlyRs in a phosphorylation state-
dependent dependent manner.  
In order to show that this priming also occurred in vivo in response to peripheral 
inflammation, we studied the effects of 2,6-DTBP on Gly-IPSCs in slices prepared from five 
mice with an inflamed hindpaw (Figure 6). Inflammation was induced by subcutaneous 
injection of zymosan A into the left hindpaw (Meller & Gebhart, 1997) and the development of 
inflammatory hyperalgesia was confirmed by monitoring mechanical response thresholds. 
Application of 2,6-DTBP did not significantly alter the Gly-IPSC amplitudes (+3.6 ± 9.7% of 
control amplitudes, p = 0.72, paired t-test) or rise times (+13.5 ± 3.8%, p = 0.09, paired t-
test). However, it significantly increased decay time kinetics by 23.5 ± 7.5% (p < 0.01, paired 
t-test). Application of vehicle instead of 2,6-DTBP did not significantly change Gly-IPSC 
amplitudes or decay time constants (data not shown). 
 
 
Figure 6. Effects of 2,6-DTBP on the amplitude and decay time of Gly-IPSCs recorded from 
lamina II neurons of mice with inflamed hindpaws. Recordings were made from the dorsal horn 
neurons ipsilateral to the inflamed paw. (A) Normalized Gly-IPSC amplitudes over time of whole cell 
recording. (B) Same as (A) but normalized decay time constant. (C) 2,6-DTBP had no significant effect 
on IPSC amplitudes, but significantly increased the decay time constant. **, p < 0.01, paired t-test, 
n = 6 cells.  
Anti-hyperalgesic activity of 2,6-DTBP in behavioral models of pain  
Finally, we investigated whether the modulatory effects of 2,6-DTBP on GlyRs translate to 
antihyperalgesic activity in inflammatory pain in vivo. To this end, we again induced 
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inflammatory hyperalgesia in mice through subcutaneous injection of zymosan A and tested 
the effects of 2,6-DTBP on mechanical and heat hyperalgesia 48 hours after zymosan A 
injection (i.e. when central sensitization had reached its maximum; (Reinold et al., 2005)). 
2,6-DTBP significantly reduced mechanical and heat hyperalgesia with a maximum response 
occurring 30 - 60 min after drug administration (Figure 7A,B). 2,6-DTBP reversed mechanical 
and heat hyperalgesia at all the time points examined (two-way repeated measures ANOVA 
followed, p < 0.05), whereas vehicle did not elicit significant effects. Consistent with our 
finding that phosphorylation was required to render GlyRs sensitive to 2,6-DTBP, we found 
that 2,6-DTBP had no analgesic effects against acute nociceptive stimuli (pin-prick) in naïve 
mice (withdrawal responses changes from 89 ± 6% to 92 ± 3% 30 - 90 min after 2,6-DTBP, p 
= 0.48, paired t-test, n = 6) (Figure S5A). To exclude possible confounding effects of 2,6-
DTBP on locomotor activity, motor coordination and muscle strength we tested the effects of 
2,6-DTBP on locomotion in an open field arena, in the accelerating rotarod test and in the 
horizontal wire test. No significant effects were observed (Figure S5B-D).  
To determine the contribution of 3GlyRs to 2,6-DTBP-induced analgesia, we compared the 
antihyperalgesic effects of 2,6-DTBP in wild-type and GlyR3-/- mice in different pain models 
(Figure 7C,D). We first address inflammatory hyperalgesia. Because previous studies have 
shown that GlyR3-/- mice recover quickly from zymosan A-induced hypersensitivity (Harvey 
et al., 2004), we switched to Freund’s adjuvant (CFA), which causes more prolonged 
hyperalgesia, and tested the effects of 2,6-DTBP at an early time point (48 hrs) after CFA 
injection. Wild-type and GlyR3-/- mice did not significantly differ in their mechanical paw 
withdrawal thresholds (PWT) at this time point and at baseline (Figure 7C). However, heat 
hyperalgesia in inflamed GlyR3-/- mice was much less pronounced than in wild-type mice 
precluding a quantitative comparison of antihyperalgesia by 2,6-DTBP in inflamed wild-type 
and GlyR3-/- mice (Figure S6). We therefore focused on mechanical hyperalgesia, which is 
also more relevant to chronic pain in human patients (Schaible 2013). 2,6-DTBP significantly 
reduced mechanical hyperalgesia in wild-type mice by 44.3 ± 5.2% (Figure 7C). In GlyR3-/- 
mice, this effect was reduced to 16.0 ± 6.2%, indicating that about two thirds of the 2,6-
DTBP-evoked analgesia came from an interaction with 3GlyRs. Previous work from our 
group suggested that phosphorylation and inhibition of GlyR3 contributes to inflammatory 
but not to neuropathic hyperalgesia (Hösl et al., 2006), while others have shown that 2,6-
DTBP still alleviated neuropathic hyperalgesia (Tibbs et al., 2013). We therefore investigated 
whether the antihyperalgesic effects of 2,6-DTBP in neuropathic pain also depended on 
GlyR3. To this end, we examined the effects of 2,6-DTBP on neuropathic hyperalgesia in 
wild-type and GlyR3-/- mice. Neuropathic hyperalgesia was induced applying a chronic 
constriction injury of the left sciatic nerve (CCI, (Bennet & Xie, 1988)). 2,6-DTBP reduced 
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hyperalgesia in both wild-type and GlyR3-/- mice to very similar degrees (Figure 7D, see 
also Figure S7). The maximum antihyperalgesic responses, which were reached between 30 
and 60 min after the drug administration, were not significantly different between wild-type 
and GlyR3-/- mice (wild-type: 46.1 ± 4.6% versus GlyR3-/-: 41.0 ± 4.7% of maximum 
possible effect, MPE), indicating that antihyperalgesic actions against neuropathic pain 
occurred independent of GlyR3. Taken together, these findings indicate that dorsal horn 
GlyRs are modulated by 2,6-DTBP in a phosphorylation state-dependent manner and that 
this modulation is particularly relevant for inflammatory hyperalgesia. 2,6-DTBP also exerts 
antihyperalgesia against neuropathic pain, but these actions occurred through mechanisms 
different from 3GlyRs possibly involving 1GlyRs (Ahrens et al., 2004) or HCN channels 
(Tibbs et al., 2013). 
 
Figure 7. In vivo antihyperalgesic effects of 2,6-DTBP. (A,B) Zymosan A model of inflammatory 
hyperalgesia. Zymosan A (0.06 mg) was injected subcutaneously into one hindpaw. 2,6-DTBP (90 
mg/kg i.p.) or vehicle were given 48 hours after zymosan A. (A) Mechanical hyperalgesia. 
Treatment*time interactions (p<0.05) were significant for time points between 30 min and 2 hrs (two-
way repeated measures ANOVA, F(1,6)=5.0–8.2). Right: maximum possible antihyperalgesic effects 
(MPE) determined for the interval 30-60 min after 2,6-DTBP injection. *, p<0.05, unpaired t-test, n=6 
and 7 mice for 2,6-DTPB and vehicle, respectively. (B) Same as (A), but heat hyperalgesia. 
Treatment*time interactions were significant for time points between 30 min and 4 hrs (F(1,6)=7.2–
24.8). MPEs: Unpaired t-test, **, p<0.01, n=7 and 6. (C) Inflammatory hyperalgesia evoked by CFA. 
2,6-DTBP was applied 2 days after CFA injection. In wild-type mice (n=7 and 9), treatment*time 
interactions were significant (p<0.05) for time points between 30 min and 4 hrs (F(1,6)=4.8–20.0). In 
GlyR3-/- mice (n=10 and 7), interactions remained insignificant for all time points (p>0.17; 
F(1,6)=0.02–0.7). Significant MPE of 2,6-DTBP (determined between 60-90 min) were found in wild-
type, but not in GlyR3-/- mice. MPE differed significantly between wild-type and GlyR3-/- mice 
(ANOVA followed by Bonferroni post hoc test, F(3,38)=9.97; ***, p<0.001, for vehicle versus 2,6-DTBP 
in wild-type mice); ++, p<0.01 (2,6-DTBP effect in wild-type versus GlyR3-/- mice). (D) Neuropathic 
hyperalgesia. 2,6-DTBP was applied 7 days after CCI. In wild-type mice, treatment*time interactions 
were significant (p<0.05) between 30 min and 90 min (F(1,6)=0.09–69.0). In GlyR3-/- mice, a 
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significant interaction (p<0.05) was found only for 60 min (F(1,6)=0.003–5.9). MPE was significant in 
wild-type and GlyR3-/- mice (ANOVA followed by Bonferroni post-hoc test, F(3,30)=24.7; ***, 
p<0.001, for 2,6-DTBP versus vehicle). No significant difference was found between 2,6-DTBP treated 
wild-type and GlyR3-/- mice (p=0.55).  
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DISCUSSION 
Our results establish the non-anesthetic propofol derivative 2,6-DTBP as an efficacious 
enhancer of glycinergic inhibition in the superficial spinal dorsal horn, a key area for central 
pain control. 2,6-DTBP not only spared GABAARs, but also was particularly effective at 3 
containing GlyRs, which are abundant in the spinal termination area of nociceptive nerve 
fibers. While homomeric 3GlyRs were potentiated by 2,6-DTBP under basal conditions, 
heteromeric ( subunit containing) GlyRs, which prevail at postsynaptic sites, were 
potentiated only in a phosphorylated (“primed”) state. In line with these results, 2,6-DTBP 
potentiated synaptic GlyR receptor currents in spinal cord slices only after priming with the 
inflammatory mediator PGE2 or in slices that were obtained from mice with peripheral 
inflammation. The phosphorylation site responsible for this priming effect is present in 
3GlyRs but absent in 1GlyRs. 
Mechanisms and sites for modulation 
When homomeric GlyR channels expressed in HEK293T cells were investigated, 2,6-DTBP 
shifted the glycine concentration response curve to the left. This leftward shift corresponds 
well with the increase in channel open probability observed in our single channel recording 
experiments. In spinal cord slices primed with PGE2, 2,6-DTBP prolonged the decay of 
synaptic GlyR currents without altering their amplitudes consistent with the observed shift in 
the glycine concentration response curve. In terms of gross glycinergic inhibition (measured 
as total charge transfer), this prolongation of the decay time course at least partially 
counteracted the reduction in the amplitude of glycinergic responses seen after PGE2.  
Our present results indicate that modulation of 3GlyRs by 2,6-DTBP depends on a single 
phenylalanine residue (F388), which is also required for the modulation of homomeric glycine 
receptors by propofol, the parent compound of 2,6-DTBP (Moraga-Cid et al., 2011). Up to 
now, a potential role in this process of the  subunit and of posttranslational modifications 
has remained unclear. In the present study we show that heteromeric 3GlyRs (in their 
non-phosphorylated state) are much less susceptible to modulation by 2,6-DTBP. This is 
consistent with the presence of an isoleucine residue instead of phenylalanine at the 
respective position in the  subunit (I443) and may in addition suggest that the presence of  
subunit prevents 2,6-DTBP from accessing its binding site in the subunit (compare Figure 
S3). Crystal structures for TM3-TM4 intracellular regions and for heteromeric Cys-loop ion 
channels are still lacking. However, our homology modeling data (Figure 3H) suggests that 
F388 lies in the so called membrane associated (MA) stretch, i.e. in a region that can 
influence some biophysical properties of ion channels (Carland et al., 2009). A comparison of 
the models of the 3-3-3 and 3--3 interfaces suggests that the volume of the  subunit 
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MA-stretch is considerably larger than that of the 3 subunit (by approximately 14500 Å3; 
Figure S8). Together with the functional data, these analyses suggest that, in homomeric 3 
GlyRs, all five potential binding sites are accessible to 2,6-DTBP, whereas the presence of  
subunits in the receptor complex decreases not only the number of acceptor sites but also 
renders the acceptor sites within the  subunits less accessible to 2,6-DTBP (at least as long 
the receptors are in the non-phosphorylated state). An unexpected finding was that the 
susceptibility of modulation by 2,6-DTBP of heteromeric 3GlyRs was restored by 
phosphorylation of (or introduction of phosphomimetic mutations in) the 3 subunit at S346. 
This observation suggests a phosphorylation-induced conformational change on the 3 
subunit permitting modulation of 3GlyRs by 2,6-DTBP (Figure S9).  
Does modulation of GlyRs contribute to analgesic actions of 2,6-DTBP? 
2,6-DTBP does not only potentiate GlyRs but also inhibits hyperpolarization and cyclic 
nucleotide gated (HCN) ion channels (Tibbs et al., 2013), in particular HCN1 channels, which 
are expressed in peripheral nociceptors and contribute to pain sensitization (Momin et al., 
2008). In addition, antioxidant properties of 2,6-DTBP (Ku et al., 1990; Shakir et al., 2014) 
may directly or indirectly (e.g. via inhibition of T-type Ca2+ channel, ref (Nelson et al., 2007)) 
contribute to antihyperalgesia. Our finding that the analgesic effects of 2,6-DTBP in mice with 
inflamed paws were reduced by about two-thirds in GlyR3-/- mice indicates that 3GlyRs 
contribute significantly to the analgesic action of 2,6-DTBP. In line with a previous report 
(Tibbs et al., 2013), we found that 2,6-DTBP was active not only against inflammatory pain 
but also against neuropathic pain caused by peripheral nerve damage. Analgesia against the 
latter was however not diminished in GlyR3-/- mice consistent with our previous data that 
suggested that phosphorylation of 3GlyRs does not contribute to neuropathic hyperalgesia 
(Hösl et al., 2006). 
In addition to strychnine-sensitive GlyRs, spinal GABAARs constitute another target that 
might allow restoring proper synaptic inhibition in the spinal cord during chronic pain states. 
GABAARs offer plenty of opportunities for pharmacological interventions, but currently 
available drugs targeting GABAARs do not exert clinically relevant analgesia mainly because 
of dose limiting sedative effects (Ralvenius et al., 2015). Targeting GlyRs offers the 
advantage that glycinergic innervation is largely restricted to the hindbrain and spinal cord, 
and almost completely spares the forebrain, where most of the unwanted actions of 
GABAergic drugs originate. Consistent with this concept, 2,6-DTBP apparently lacks effects 
on locomotor activity, motor coordination and muscle strength, which are typical side effects 
of classical GABAergic drugs such as the benzodiazepines. It is likely that both the low 
abundance and absence of glycinergic innervation in the forebrain and specific modulation of 
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phosphorylated GlyRs contribute to this favorable profile.  
2,6-DTBP did not only show a preference for GlyRs over GABAARs but also preferred the low 
abundance 3GlyRs over the much more prevalent 1GlyRs; the other two GlyRs isoforms 
(2 and 4GlyRs) are less relevant as drug targets as2GlyRs are mainly expressed during 
prenatal and early postnatal development (Lynch, 2009), while the gene encoding the 4 
subunit is a pseudogene in humans (Laube et al., 2002; Simon et al., 2004). Compared to 
1GlyRs, which are found throughout most parts of the spinal cord and hindbrain, 3GlyRs 
are expressed in a spatially much more restricted manner. In the spinal cord, 3GlyR 
expression is limited to the superficial layers of the dorsal horn (Harvey et al., 2004), while at 
supra-spinal sites, 3GlyR expression is generally weak and found only in a few sites, such 
the retina (Haverkamp et al., 2003), cerebellum and the hippocampus (Malosio et al., 1991). 
The preferential potentiation of 3GlyRs may thus help avoiding unwanted effects such as 
strong muscle relaxation.  
An additional level of specificity comes from the dependence of modulation of synaptic GlyRs 
on prior phosphorylation. Most postsynaptic GlyRs are heteromers containing in addition to  
subunits also subunits, which anchor the channel complexes to postsynaptic sites. Our 
experiments revealed that, under resting (non-phosphorylated) conditions, heteromeric 
3GlyRs were much less sensitive to modulation by 2,6-DTBP than homomeric receptors. 
However, introduction of a phosphomimetic amino acid exchange in the 3 subunit of 
recombinant 3GlyRs restored susceptibility to modulation by 2,6-DTBP. Accordingly, 
native postsynaptic GlyRs of the spinal dorsal horn were only modulated after priming 
through pretreatment of spinal cord slices with PGE2, which leads to PKA-dependent 
phosphorylation of 3GlyRs, or, when slices were taken from mice with an inflamed hindpaw. 
Importantly, the consensus site for PKA-dependent phosphorylation of GlyR 3 subunits is 
missing from the 1 subunit introducing again an additional level of specificity. The absence 
of this site in GlyR 1 subunits may explain why we did not find effects of 2,6-DTBP on 
muscle strength although GlyRs effectively control motoneuron excitability. 
Recordings of synaptic GlyR currents in slices obtained from naïve (non-inflamed) mice were 
not modulated by 2,6-DTBP suggesting that homomeric 3GlyRs lacking GlyR subunits do 
not make a measureable contribution to synaptic inhibition in the dorsal horn. However, 
homomeric receptors may be present at extrasynaptic sites where they mediate tonic 
currents. In line with a previous report (Mitchell et al., 2007) we found tonic currents only in a 
small portion of cells and these currents were of very small (≤ 5 pA) amplitudes. In certain 
areas of the brainstem, homomeric 1GlyRs have been reported to be present in presynaptic 
terminals where they control transmitter release (Xiong et al., 2014; Hruskova et al., 2012). 
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The lack of modulation of glycinergic synaptic currents by 2,6-DTBP suggests that such 
homomeric presynaptic GlyRs are not present in the superficial dorsal horn. It is however 
possible that such receptors exist at other sites and that interaction with these receptors 
might cause effects of 2,6-DTBP on behaviors of mice not studied here. 
In summary, our results describe a phosphorylation state-dependent interaction of a propofol 
derivative with inflammation-primed synaptic GlyRs in the spinal dorsal horn. Reduced 
analgesic effects in GlyR3-deficient mice suggest that this phosphorylation-dependent 
potentiation contributes to the analgesic effects of 2,6-DTBP against inflammatory pain 
(Figure S10). These results provide direct evidence that diminished inhibitory pain control in 
the spinal cord can be restored by positive allosteric modulation of GlyRs and may pave the 
path for the generation of new spinally-acting analgesics with limited supraspinal side effects. 
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Supplementary Figures and Tables 
 
Figure S1. Picrotoxin sensitivity of recombinant GlyRs. Concentration-response curves of 
picrotoxin (PTX, 0.01 - 100 M) were obtained using the EC50 of glycine for each GlyR subtype (1: 45 
M, 3: 200 M, 1M, 3 210 M). The entire PTX concentration range was tested on each 
cell. Coexpression of the  subunit significantly reduced picrotoxin sensitivity of 1 and 3 GlyRs, 
confirming the presence of heteromeric channel complexes containing both  and  subunits. Data are 
mean ± SEM from 6 - 9 cells per group. *, p < 0.05, unpaired t-test.  
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Figure S2. Glycine sensitivity of homomeric and / heteromeric 3(S346A) and 3(S346E) 
point mutated GlyRs expressed in HEK293T cells.  
 
 
Figure S3. Structural model of GlyRsubunit. (A) Primary sequence alignment of the MA-stretch 
region of GlyR3 and GlyR subunits. The conservation scores are also shown (maximum 11, 
minimum 1). The identity percentage only reached 32%. (B) Homology model of  subunit monomer 
oriented in the plasma membrane. The location of the I443 residue (which is the counterpart of the 
F388 in 3GlyR) is highlighted in red. (C) Detailed view of the theoretical acceptor site of 2,6-DTBP in 
GlyR
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Figure S4. Effects of 2,6-DTBP on tonic glycinergic membrane currents lamina II neurons. 
Recordings were made in the presence of CNQX (5 μM), D-APV (50 μM) and bicuculline (10 μM). (A) 
Example trace during control conditions, after application of 2,6-DTBP (100 M) and after additional 
application of strychnine (1 μM). (B) The all-point histograms indicate the holding current amplitudes 
under these three conditions. (C) 2,6-DTBP did not significantly affect the holding current (+4.6 ± 7.6% 
of control amplitudes, p = 0.56, paired t-test).  
 
Figure S5. Effects of 2,6-DTBP on locomotor activity, motor coordination, muscle relaxation 
and acute pain. (A) 2,6-DTBP had no effect on acute nociceptive pain assessed in the pin-prick test 
in wild-type mice. (B) Locomotor activity (number of beam crosses in an open field arena, mean ± 
SEM) of wild-type mice after the administration of vehicle or 2,6-DTBP. n = 8 mice per group, p = 0.31, 
unpaired t-test. (C) Motor coordination (normalized time spent on an accelerating rotarod, mean ± 
SEM) of wild-type mice after the administration of vehicle or 2,6-DTBP (n = 7 – 9 mice per group, p = 
0.39, unpaired t-test). (D) Muscle strength assessed in the horizontal wire test (percent number of 
successful attempts, mean ± SEM).  
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Figure S6. Effects of 2,6-DTBP on heat hyperalgesia in wild-type and in GlyR3-/- mice after 
injection of CFA. Paw withdrawal latencies at baseline and 48 hrs after subcutaneous CFA injection. 
ANOVA followed by Bonferroni post-hoc test. F(3,61) = 10.38. ***, p < 0.001 WT pre-CFA versus WT 
post-CFA, ++, p < 0.01, WT post-CFA versus GlyR3-/- post-CFA.  
 
 
Figure S7. 2,6-DTBP effects on heat hyperalgesia in neuropathic (CCI) wild-type and GlyR3-/- 
mice. (A) 2,6-DTBP or vehicle were applied (90 mg/kg, i.p.) on day 7 after CCI surgery. (B) ANOVA 
followed by Bonferroni post hoc test. F(3,25) = 9.42. **, p < 0.01, *, p < 0.05 before versus after 2,6-
DTBP.  
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Figure S8. Structural models of the 3-3-3 and 3-3subunit interfaces. Graphic 
representation of a homotrimeric assembly composed of identical 3 subunits (upper panels, 3 
subunits in cyan) and of a heterotrimeric assembly composed by a single  subunit (in yellow) flanked 
by two 3 subunits (lower panels). Right panels, magnifications of the regions indicated on the left 
encircling the putative acceptor sites for 2,6-DTBP in the GlyR3 MA-stretch. The F388 residue in the 
GlyR3 subunit and the I443 residue in the GlyR  subunit are highlighted in red and purple, 
respectively. Calculated volumes of the magnified regions are 39260 Å3 and 53750 Å3, for the 3-3-
3 and the 3--3 assemblies, respectively.  
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Figure S9. Molecular requirements for allosteric modulation by 2,6-DTBP of 3 and 3 GlyRs 
with phosphorylated or dephosphorylated GlyR3 subunits. (A) Dephosphorylated homomeric 
GlyR3 are positively modulated by 2,6-DTBP. PKA-dependent phosphorylation of S346 changes the 
GlyR conformation without preventing the modulation by 2,6-DTBP. (B) Heteromeric 3GlyRs display 
a low sensitivity to modulation by 2,6-DTBP in their dephosphorylated state possibly due to the 
occlusion of the 2,6-DTBP  interacting site by the  subunit.  
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Figure S10. Proposed mechanism of the antihyperalgesic action for 2,6-DTBP. Presynaptic 
terminals of inhibitory interneurons release the neurotransmitters GABA and glycine into the synaptic 
cleft, allowing the phasic activation of postsynaptic GABAA and GlyRs. Under physiological conditions, 
the chloride influx through these ligand-gated ion channels provides efficient inhibitory control of 
excitatory neuron activity. Peripheral inflammation stimulates the production of spinal PGE2, which 
subsequently activates EP2 receptors and stimulates PKA-dependent phosphorylation of synaptic 
GlyRs containing 3 subunits. Phosphorylation reduces the inhibitory postsynaptic currents through 
heteromeric 3GlyRs and disinhibits dorsal horn neurons, which may contribute to the development 
and maintenance of hyperalgesic states. 2,6-DTBP selectively modulates synaptic 3GlyRs in their 
phosphorylated states, allowing a restoration of the glycinergic control over the relay of nociceptive 
signals to higher CNS centers. 
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Table S1. Concentration-response curves of recombinant GlyRs expressed in 
HEK293T cells.  
 
Concentration-response parameters were obtained from fits of normalized current amplitudes to the 
equation  Igly = Imax[gly]nH/([gly]nH + [EC50]nH). The mean maximal current (Imax) indicates the 
average maximal current elicited by a saturating concentration of glycine (1 mM). Data were calculated 
from current responses activated by 1, 10, 30, 60, 100, 200, 500, and 1000 M glycine recorded at a 
holding potential of -60 mV. All values are mean ± SEM. 
  
 EC50 (M) nh Imax (nA) number of cells 
3 133±15 1.7±0.25 4.3±1.1 8 
1 54±3.0 2.1±0.21 4.2±0.8 9 
3 117±5.0 3.0±0.32 4.0±1.0 9 
1 98±4.0 1.9±0.12 4.6±1.0 6 
3 S346A 104±2.1 3.0±0.16 5.7±0.6 18 
3 S346E 101±2.6 2.7±0.17 3.9±0.7 16 
3 S346A 257±10.5 2.3±0.16 3.5±0.5 5 
3 S346E 259±11.0 2.5±0.21 4.3±0.6 5 
3 F388A 79±12.3 1.7±0.27 3.6±0.6 7 
3 S346E-F388A 125±8.1 1.54±0.13 2.9±0.8 3 
3 S346E-F388A 81±6.2 1.7±0.25 4.3±1.2 4 
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Table S2. Single-channel kinetic parameters of wild-type and mutant 3GlyRs in the 
absence or the presence of 2,6-DTBP. 
 
*, p <0.05, t-test, wild-type versus (F388A) point mutated 3GlyR. 
+, p < 0.05, paired t-test, control condition versus 2,6-DTBP  
MOT, mean open time; MST, mean shut time; nPo, open probability; , conductance. 
 
 
 
 
Table S3. Binding energy and docking scores of different propofol analogs 
on3GlyRs.  
 
percentage 
potentiation  
on 3GlyR 
docking 
score 
∆G binding 
(kcal/mol) dock*∆G index 
2,4-di-tert-butylphenol 
 482±96 -2.79 -40.484 112.950 
2,6-di-isopropyl-phenol (propofol) 442±99 -2.505  
-38.708 
 
96.962 
 
2,6-di-tert-butylphenol 171±21 -2.133 -42.086  
89.784 
 
2,6-di-methoxi-phenol 3.0±20 -2.476 -32.177  
79.669 
 
 
Percent potentiation of wild-type 3GlyRs was calculated from experimental data using a modulator 
concentration of 100 M. 2,6-di-methoxi-phenol was inactive on 3GlyRs and showed the lowest 
Dock*∆G index. Dock*∆G reflects the relationship between the docking attributes of each modulator 
with their binding energy at the respective site. Percent potentiation and the Dock*∆G index show a 
linear correlation (r = 0.92, p = 0.08). 
 
 
 
   
GlyR3 
Glycine (100 µM) Glycine (100 µM)/2,6-DTBP (10µM)  
MOT 
(ms) 
MST  
(ms) 
nPo 
 
Main  
(pS) 
MOT  
(ms) 
MST  
(ms) 
nPo 
 
Main  
(pS) 
WT 21.6 
±6.0 
310.0 
±60.5 
0.20 
±0.02 
91.0 
±1.20 
55.6 
±8.19+ 
139.2 
±21.5+ 
0.58 
±0.10+ 
90.1 
±0.92 
F388A 19.1 
±3.2 
201.6 
±51.9 
0.18 
±0.05 
88.2 
±1.82 
18.1 
±4.89 
213.6 
±27.8 
0.19 
±0.04* 
88.7 
±1.46 
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Chapter II: Pharmacological Modulation of 
Canonical and Non-Canonical 
Benzodiazepine-Binding Sites by Selected 
Benzodiazepine Site Ligands 	
 
 
In the following chapter, I describe the in vitro pharmacological profile of selected benzodiazepine‐
binding site ligands (BDZs) on GABAARs. There are two major sections, one characterizing the 
pharmacological profile of BDZs with reduced sedative properties at canonical γ2‐containing 
GABAARs. In this section, I compare their differential sensitivity to all four BDZs sensitive subtypes 
(α1, α2, α3 and α5GABAARs). In the second section, I characterize the sensitivity of selected BDZs at 
non‐canonical benzodiazepine‐binding sites, specifically those containing the γ1 subtype. 
 
Part of this work has been published and is paraphrased from the original article:  
*William T. Ralvenius, *Mario A. Acuña, Dietmar Benke, Alain Matthey, Youssef Daali, Uwe Rudolph, 
Jules Desmeules, Hanns Ulrich Zeilhofer, Marie Besson . The clobazam metabolite N‐desmethyl 
clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for 
antihyperalgesia. Neuropharmacology 2016. 
*Co‐first authors 
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ABSTRACT 
Spinal disinhibition arises from different mechanisms including a decrease in GABAergic 
neurotransmission. Data from point mutated mice suggest that benzodiazepine-site agonists 
(BDZs) with preferential activity at α2-containing GABAARs represent a useful tool for 
restoring spinal inhibition. Here I first analyzed the effect of clobazam (CBZ), its main 
metabolite N-desmethyl clomabzam (NDMC) and of diazepam (DZP) on recombinant 
GABAARs. DZP and CBZ potentiated α1GABAARs and α2GABAARs with similar efficacies, 
whereas NDMC showed higher efficacy at α2GABAARs over α1GABAARs across a wide 
concentration range. Then we studied the modulatory effects of a novel BDZ, HZ-166. This 
compound not only showed higher efficacy at α2GABAARs over α1GABAARs, but also 
greater potency. Finally we assessed the potentiation profile of TP003 and TPA023B. TP003 
displayed higher efficacy at α2 and α3GABAARs over α1GABAARs. However, TPA023B 
showed the most profound difference with high potency and efficacy at α2 and α3GABAARs 
and negligible effects at α1GABAARs. Although the γ2 subunit is required for full potentiation 
by BDZs, γ1-containing GABAARs still possess sensitivity to certain BDZs. Moreover, 
previous data suggest that differences in the pharmacological effects of BDZs cannot only be 
explained based on their actions at the BDZ-sensitive α subunits. Therefore, I studied the 
modulatory activity of the BDZs at γ1GABAARS. Among all the BDZs tested HZ-166 showed 
the highest efficacy at α2β3γ1GABAARs. This effect was dependent on the BDZ-binding site 
at the α2 subunit. When tested at α1β2γ1GABAARs, HZ-166 showed negligible effects. Other 
results obtained by us and by other groups suggest that γ1 containing GABAARs are 
expressed in the spinal dorsal horn. Together with these data, my results open the possibility 
that part of the analgesic action of HZ-166 and potentially of other BDZs originate from dorsal 
horn GABAARs that contain γ1.  
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INTRODUCTION 
Canonical BDZ-binding site: modulation of γ2-containing GABAARs 
In chronic pain states, the dorsal spinal cord undergoes plastic changes leading to the so-
called disinhibition. Research of the last two decades has identified mechanisms underlying 
the reduction of inhibitory synaptic transmission in inflammatory or neuropathic pain states. i) 
In inflammatory pain, a prostaglandin E2-mediated phosphorylation of dorsal GlyRs renders 
these receptors less responsive to glycine (Ahmadi et al., 2002, Harvey et al., 2004). ii) 
Activated microglia down-regulate the expression of the potassium/chloride transporter 
KCC2 in superficial dorsal horn neurons after peripheral nerve injury (Coull et al., 2003, Coull 
et al., 2005, Keller et al., 2007). iii) Extensive nociceptor activation inhibits GABAergic 
interneurons (Pernia-Andrade et al., 2009). And iv) peripheral nerve damage leads to a 
down-regulation of the GABA synthesizing enzyme GAD65 in the spinal cord (Moore et al., 
2002), and both inflammation and neuropathic nerve injury cause an epigenetic down-
regulation of the same enzyme in the brainstem (Zhang et al., 2011). 
GABAA receptors are heteropentameric ligand-gated ion channels. Although a very large 
number of genes encode for GABAAR subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3), most of 
neuronal GABAARs are composed of α, β, γ, or δ subunits in a 2α:2β:1γ or 2α:2β:1δ 
stoichiometry. The majority of GABAARs in the CNS are sensitive to positive allosteric 
modulation by classical benzodiazepines-binding site ligands (BDZs), which bind to a site 
formed by one of four α subunits (α1, α2, α3 or α5) and the γ2 subunit (Wieland et al., 1992). 
Using point mutated mice carrying BDZ-insensitive α subunits, our group elucidated the 
contribution of the different α subunits to BDZ-mediated antihyperalgesia and to attribute this 
effect mainly to α2 and α3 GABAA receptors (Knabl et al., 2008). Moreover, taking advantage 
of the generation of triple GABAAR point mutated mouse lines, we have found that the 
highest antihyperalgesic efficacy was attributable to α2-containing GABAARs (α2GABAARs) 
and adding activity at α3 or α5GABAARs increases antihyperalgesic efficacy only moderately 
or not at all (Ralvenius et al., 2015). On the other hand, targeting α1GABAARs leads to 
sedation and motor impairment. Therefore, subtype-selective BDZ agonists targeting only 
α2GABAARs should have the best benefit-risk ratio. 
In this chapter, I have analyzed the pharmacological profile of CBZ, NDMC, DZP, HZ-166, 
TP003 and TP023B. Previous studies have shown that the antihyperalgesic effects of 
clobazam (CBZ) - a licensed BDZ with reduced sedative properties - correlated better with 
blood levels of the main metabolite N-desmethyl clobazam (NDMC) than with blood levels of 
CBZ (Besson et al., 2013). The novel non-sedative 8-acetyleno-2’-
pyridoimidazobenzodiazepine HZ-166 (Rivas et al., 2009) has been shown to exert 
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antihyperalgesia with no obvious sedative effects (Di Lio et al., 2011, Paul et al., 2014) and 
with better pharmacokinetic properties in mice than L-838,417 (Scott-Stevens et al., 2005). 
TP0A23B is a novel non-sedative anxiolytic imidazotriazine with negligible action at 
α1GABAARs, modulating specifically those receptors containing the α2 and α3 subunit (Atack 
et al., 2011). TP003 is an anxiolytic compound, which has been shown to have specific 
modulatory activities only at α3GABAARs and negligible efficacy at the α1, α2 and 
α5GABAARs (Dias et al., 2005). 
A thorough analysis of such compounds at all BDZ-sensitive GABAARs will thus reveal a 
pharmacological profile aiming to find specific modulators for GABAARs containing the α2 
subunit, which mediates the antihyperalgesic action of BDZs.  
Non-canonical BDZ-binding site: modulation of γ1-containing GABAARs 
The restoration of the spinal inhibitory pain control through the modulation of specific 
GABAAR subunits is a new approach for pain therapy. So far, all the motivation has been 
placed on the study of selective modulators for different α subunits of the GABAARs. Several 
lines of evidence from our lab suggest that differences in the pharmacological effects of BDZ 
site agonists cannot be explained solely on the basis of their differential actions at distinct α 
subtypes. Alternatively, some differences may originate from different subtypes of γ subunits 
included in the GABAAR complex. HZ-166, acting on α2 or α3 containing GABAAR, has 
analgesic effects, but is not muscle-relaxant (Di Lio et al., 2011, Paul et al., 2014). 
Flumazenil can antagonize the antihyperalgesic effect of spinally applied DZP only at high 
concentrations (Knabl et al., 2008). The specific ablation of γ2 subunit in primary nociceptors 
has no influence on the analgesic effects of spinally-applied DZP, although these effects are 
significantly reduced when α2 is ablated (Witschi et al., 2011). In mice carrying the H  R 
point mutation in the α2 subunit, which renders α2GABAARs insensitive to BDZs, the 
antihyperalgesic effects of spinally-applied DZP were reduced by about 80% (Knabl et al., 
2008), but spinal flumazenil binding sites are reduced only by < 10% (Ralvenius et al., 2015). 
DMCM, an antagonist at γ2-GABAARs but agonist at γ1-GABAARs, displays antihyperalgesic 
effects in neuropathic & inflammatory pain models (Munro et al., 2011). 
Remarkably, among the three known γ subunits, γ2 is the most expressed in the brain 
(Mohler et al., 2002, Fritschy and Brunig, 2003). The possibility of targeting ‘non-γ2’-
GABAARs might therefore lead to a selectivity of GABAAR modulation and thus establish a 
new possibility for spinal GABAAR-mediated analgesia. Although classical BDZs require the 
γ2 subunit for full potentiation, γ1 and γ3-containing GABAARs are still sensitive to certain 
BDZ site ligands (McKernan et al., 1995, Esmaeili et al., 2009). Therefore, we aimed to 
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pharmacologically characterize the sensitivity of γ1-containing GABAARs to different BDZ-site 
ligands, namely DZP, HZ-166, CGS-20625, TPA023B and NDMC.  
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METHODS 
Electrophysiology. The effects of DZP, CBZ, NDMC, HZ-166, TPA023B and TP003 on 
currents through recombinant GABAARs were studied in HEK293 cells transiently transfected 
with rat GABAAR subunits using lipofectamine LTX 46 (Invitrogen). To ensure expression of 
the γ2 or γ1 subunit in all recorded cells, we transfected cells with a plasmid expressing the 
γ1/2 subunit plus eGFP from an IRES, and selected only eGFP-positive cells for recordings 
(see also (Ralvenius et al., 2015)). The transfection mixture contained (in µg): 1 αx, 1 βy, 3 
γ1-2/eGFP. Whole-cell patch-clamp recordings were made 18 – 36 hrs after transfection at 
room temperature (20 – 24°C) and at a holding potential of -60 mV. Recording electrodes 
were filled with solution containing (in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 7.40), 4 
MgCl2, 0.5 GTP and 2 ATP. The external solution contained (in mM): 150 NaCl, 10 KCl, 2.0 
CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.40), and 10 glucose. GABA was applied to the recorded 
cell using a manually controlled pulse (6 - 10 s) of a low sub-saturating GABA concentration 
(EC5-10). EC5-10 values of GABA applied for the four canonical benzodiazepine-sensitive 
GABAAR combinations (α1β2γ2, α2β3γ2, α3β3γ2 and α5β2γ2) and non-canonical 
benzodiazepine γ1-containing GABAARs (α1β2γ1, α2β3γ1, α3β2γ1). EC50 values and Hill 
coefficients (nH) were obtained from fits of normalized concentration-response curves to the 
equation IGABA = Imax [GABA]nH / ([GABA]nH + [EC50]nH). Imax was determined as the average 
maximal current elicited by saturating concentration of GABA (30 µM – 3 mM, depending on 
the subunit composition). DZP, CBZ, NDMC, HZ-166, TP003 and TPA023B, CGS 20625 
were dissolved in DMSO (final concentration < 0.1%) and subsequently diluted on the day of 
the experiment in external solution and were co-applied with GABA without preincubation. 
Concentration-response curves were fitted using the equation for sigmoidal concentration-
response curve with variable slope: E(C) = (Emax · [C]nH) / ([C]nH + [EC50]nH). 
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RESULTS 
Characterization of canonical BDZ-sensitive GABAARs 
Modulatory effects of DZP, CBZ and NDMC at all BDZ-sensitive GABAARs1 
In this section, I compared the pharmacological profile of the CBZ metabolite NDMC with 
CBZ and DZP. More specifically I analyzed the positive allosteric modulation by these 
compounds on recombinant GABAARs expressed in HEK293 cells (Figure 1). In 
electrophysiological experiments, all three compounds potentiated currents through α1β2γ2, 
α2β3γ2, α3β3γ2 and α5β2γ2GABAARs (short α1-, α2-, α3- and α5GABAARs) but did not 
directly activate GABAAR currents at the concentrations tested (up to 3 µM for DZP, and 20 
µM for CBZ and NDMC). Differences were observed with respect to the potency and efficacy 
of the three compounds at the four GABAAR subtypes. DZP potentiated currents through all 
four subtypes with EC50 values between 0.029 and 0.071 µM (Figure 1B). CBZ and NDMC 
were less potent with EC50 values between 0.40 and 1.1 µM and between 0.49 and 0.81 µM, 
respectively (Figure 1C,D). Pronounced differences were found when comparing the efficacy 
of potentiation by the three compounds at the different GABAAR subtypes. Potentiation by 
DZP was strongest for α3GABAARs, while potentiation of the other three GABAAR subtypes 
ranged between 100% and 141%. At concentrations < EC50, which are probably more 
relevant to therapeutic effects of DZP, α1GABAARs were potentiated more strongly than α2-, 
α3- and α5GABAARs. CBZ and DZP had very similar efficacies at the four GABAAR 
subtypes, but CBZ differentiated less between subtypes at sub-saturating concentrations. 
NDMC potentiated α2 and α3GABAARs to a considerably higher degree (253 and 245%) 
than α1 and α5 (143 and 148%) (Figure 1D). This potentiation was negligible at GABAARs 
carrying the BDZ-insensitive (α2H-RGABAARS) subunit (Figure 2). Taken together, DZP 
preferred α1GABAARs at low concentrations and α3GABAARs at high concentrations. CBZ 
was rather non-specific at low concentrations and preferred α3GABAARs at high 
concentrations, while NDMC showed the strongest potentiation at α2GABAARs over the 
concentration range tested. 
                                                            
1 This section, including Figure 1, was reproduced from its original version published in 
Neuropharmacology by Ralvenius WT & Acuña MA et al., 2016. 
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Figure 1. Potentiating effects of DZP, CBZ and NDMC on the four BDZ-sensitive GABAAR 
subtypes. (A) Chemical structure of DZP, CBZ, and NDMC. (B-D) GABA-evoked membrane currents 
were measured in HEK293 cells transiently transfected with recombinant α1β2γ2 (grey and black), 
α2β3γ2 (light and dark red), α3β3γ2 (light and dark green), and α5β2γ2 (light and dark blue) 
GABAARs. Top panels, traces show current responses evoked by GABA before and during application 
of a saturating concentration of DZP, CBZ, or NDMC (1 µM in case of DZP, and 20 µM in case of CBZ 
and NDMC). Light and dark traces before and during application of the BDZ, respectively. GABA was 
applied at EC10 in all experiments (1 µM, 5 µM, 8 µM, and 1 µM, for α1β2γ2, α2β3γ2, α3β3γ2, and 
α5β2γ2 GABAARs, respectively) for 6 -10 s. Scale bars, 2 s and 200 pA. Bottom panels, concentration 
response curves of DZP, CBZ and NDMC obtained for the four GABAAR subtypes at EC10 of GABA. 
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Data are mean ± SEM. Curves represent fits to Hill’s equation with a baseline fixed to 0. n, numbers of 
cells = 5 – 7 for all data points.	
	
Figure 2. Lack of modulation by NDMC (1 µM) of α2(H-R)β3γ2 point mutated GABAARs. (A) Loss 
of sensitivity in the point mutated α2(H-R)β3γ2 GABAAR. n = 5 per condition. Unpaired t test **, P < 
0.01. Data are mean ± SEM. (B) Representative GABA (EC10)-evoked traces and NDMC (1 μM) in WT 
α2β3γ2GABAARs and BDZ-insensitive α2(H-R)β2γ2GABAARs. Grey and black traces indicate before 
and during application of NDMC, respectively. Scale bars, 2 s and 200pA. 
 
GABAAR modulation by HZ-166 
Using the same methodology as in the previous section, I studied the effect of HZ-166 as 
positive allosteric modulator of GABAARs expressed in HEK293 cells (Figure 3). HZ-166 
potentiated all four combinations of GABAARs, although differences were observed in terms 
of potency and efficacy at the four GABAAR subtypes. HZ-166 showed the highest potency at 
α2GABAARs (EC50 (mean ± SD) value of 0.167 ± 0.0107 μM), which is about 8-times higher 
than at α1GABAARs (EC50 (mean ± SD) value of 1.3 ± 0.7 μM). In the case of α3 and 
α5GABAARs, HZ-166 showed similar potency at those combinations (EC50 (mean ± SD) 
values for α3 of 0.50 ± 0.112 μM and for α5 of 0.47 ± 0.089 μM). At concentrations < EC50, 
which are probably more relevant to therapeutic effects, α2- and α3- GABAARs were 
potentiated more strongly than α1 and α5GABAARs. Similarly to NDMC, HZ-166 potentiated 
α2 and α3GABAARs to a higher degree (155.1 ± 15 and 184.8 ± 12%, mean ± SEM) than α1 
and α5GABAARS (116.6 ± 10% and 112 ± 21%, mean ± SEM) at saturating concentrations. 
These data indicate that HZ-166 preferred α2 and α3GABAARs with high potency and 
efficacy, making it an interesting candidate for future behavioral studies on pain. 
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Figure 3. Modulation of GABAARs by HZ-166. (A) Concentration-response curves for HZ-166 
obtained for α1β2γ2 (black), α2β3γ2 (red), α3β3γ2 (green) and α5β2γ2 (blue). Data are mean ± SEM. 
Curves represent fits to Hill’s equation with a baseline fixed to 0. n, numbers of cells, = 5 – 6 for all 
data points. (B) GABA-evoked membrane currents were measured in HEK293 cells transiently 
transfected with recombinant α1β2γ2  (grey and black), α2β3γ2 (light and dark red), α3β3γ2 (light and 
dark green), and α5β2γ2 (light and dark blue) GABAARs. Scale bars, 2 s and 200pA. GABA at EC5 
was applied in all experiments. 
 
GABAAR modulation by TPA023B and TP003 
I next analyzed the effects of two novel BDZ site ligands, TPA023B (Atack, Hallett et al. 
2011) and TP0003 (Dias, Sheppard et al. 2005) in recombinant GABAARs. Although these 
compounds have been characterized before, I considered that it is important to replicate the 
earlier studies in order to obtain own data on the actions of these drugs. Moreover, a recent 
study has shown conflicting results regarding the specificity of TP003 acting at α3GABAARs. 
It has been shown that TP003 unexpectedly potentiated GABAARs at all four BDZ-sensitive 
combinations (de Lucas et al., 2015) contradicting what was found previously (Dias et al., 
2005). Therefore, I decided to perform in-house characterization of the modulatory activity of 
TPA023B and TP003. TP003 shows higher potency at α3GABAARs compared to the α1, α2, 
and α5GABAARs (EC50 (mean ± SD) values for α1, α2, α3 and α5GABAARs: 20 ± 3.2 nM, 10 
± 3 nM,  3 ± 1 nM and 5.6 ± 1 nM, respectively) (Figure 4A). This compound also shows 
higher efficacy at α3GABAARs over the range of concentration tested, but similar efficacies at 
α2 and α5GABAARs with lower efficacy at α1GABAARS. Conversely, TPA023B showed 
efficacy only at α2 and α3GABAARs, with small potentiation at α5 (only at saturating 
concentrations) and no activity at α1 (Figure 4B). Although this compound showed lower 
potency at α2 and α3GABAARs than TP003, it remarkably exhibited a preferential action on 
α2/3 with negligible efficacy at α1GABAARs. Modulatory activity of TPA023B, in terms of 
efficacy and potency, at α2 was comparable to α3GABAARs (EC50 (mean ± SD). Values for 
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α2 and α3GABAARs are 51 ± 18 nM and 35 ± 10 nM, respectively; and maximal efficacy 
values are 107.3 ± 18% and 109.4 ± 24%, respectively). 
 
Figure 4. Potentiating effects of TP003 and TPA023B on the four BDZ-sensitive GABAARs. 
Concentration-response curves obtained for α1β2γ2 (black), α2β3γ2 (red), α3β3γ2 (green) and 
α5β2γ2 (blue) for TP003 (A) and TPA023B (B). Data are mean ± SEM. Curves represent fits to Hill’s 
equation with a baseline fixed to 0. n, numbers of cells, = 5 – 6 for all data points.  
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Characterization of non-canonical BDZ-sensitive GABAARs 
To characterize the sensitivity to selected BDZs of γ1 versus γ2-containing GABAARs, I 
performed whole-cell patch clamp experiments in HEK239 cells expressing either αx/βy/γ2 
GABAARs or αx/βy/γ1 GABAARs. The first step was to test whether γ1 and γ2-containing 
GABAARs were functionally assembled at the cell membrane. We took advantage of the 
differential sensitivity to Zn2+ of receptors containing or not γ subunits (Draguhn et al., 1990, 
Smart et al., 1991). α2/β3 subunit combinations showed high sensitivity, whereas the 
inclusion of any γ subunit to the receptor complex rendered the receptor less sensitive to the 
inhibitory effects of Zn2+ (Figure 5) (IC50 values for α2β3GABAARs and α2β3γ1/2GABAARs 
are (mean ± SD) 0.39 ± 0.16 μM, 32 ± 1.7 μM and 131 ± 136 μM, respectively). These data 
thus verify the incorporation of the γ1 subunit into the GABAAR complex. 
 
Figure 5. Zn2+ potency is affected by the inclusion of γ1 and γ2 subunits in the GABAAR 
complex. Concentration inhibition curves determined for α2β3, α2β3γ1 and α2β3γ2GABAARs using 
an EC50 of GABA. Data was fitted to Hill’s equation n = 3 – 6 cells for all data points.   
I further characterized different BDZs, namely diazepam, HZ-166, CGS20625, TPA023B and 
NDMC at α2β3γ1GABAARs and compared the sensitivity to α2β3γ2GABAARS. We selected 
only the α2-containing GABAARs, because these receptors are the most relevant for spinal 
GABAARs-mediated antihyperalgesia (Knabl et al., 2008, Ralvenius et al., 2015). All of the 
drugs tested potentiated GABAARs in the configuration α2β3γ1 (Figure 6A-C). DZP showed 
lower potency (EC50 (mean ± SD) values are 30.8 ± 6.98 μM and 0.12 ± 0.01 μM, for α2β3γ1 
and α2β3γ2GABAARS, respectively) but similar efficacy as α2β3γ2 at each corresponding 
maximal concentration tested (Figure 6A) (Emax (mean ± SEM) values are 101 ± 12% and 94 
± 16.5% for α2β3γ1 and α2β3γ2GABAARs, respectively). Unexpectedly, at saturating 
concentrations, the efficacy by HZ-166 was stronger at γ1-containing GABAARs than at 
γ2GABAARs (Emax (mean ± SEM) values are 374.7 ± 108% and 162.7 ± 19.5% for α2β3γ1 
and α2β3γ2GABAARs, respectively), whereas it showed lower potency at γ1GABAARs (EC50 
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(mean ± SD) values are 8.8 ± 2.3 μM and 0.15 ± 0.01 μM, for α2β3γ1 and α2β3γ2GABAARs, 
respectively). Moreover, this modulation was dependent on the presence of the γ subunit, 
since HZ-166 had negligible activity at α2β3GABAAR (0.5 ± 7% vs 374.7 ± 108% in α2β3 
versus α2β3γ1GABAARs, respectively; unpaired t-test p<0.05, n = 3 - 5). CGS 20625, a 
compound that has positive allosteric modulation activity at α1β2γ1 (Khom et al., 2006), 
showed increased efficacy at α2β3γ1 at low concentrations over α2β3γ2GABAARs. TPA023B 
differentiated strongly between subtypes, acting with lower potency (EC50 (mean ± SD) 
values are 0.74 ± 0.01 μM and 0.055 ± 0.02 μM, for α2β3γ1 and α2β3γ2GABAARS, 
respectively) and decreased efficacy (Emax (mean ± SEM) values are 54.1 ± 6.7% and 107 ± 
18% for α2β3γ1 and α2β3γ2GABAARs, respectively). Pronounced differences were also 
found when comparing the efficacy and potency by NDMC at γ1 and γ2GABAARs. 
Potentiation by NDMC was stronger at α2β3γ2 than α2β3γ1GABAARS, showing higher 
potency (EC50 (mean ± SD) values are 2.5 ± 3.4μM and 0.58 ± 0.27 μM, for α2β3γ1 and 
α2β3γ2GABAARS, respectively) and efficacy (Emax (mean ± SEM) values are 79.6 ± 6.7% 
and 198 ± 48.7% for α2β3γ1 and α2β3γ2GABAARs, respectively).  
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Figure 6. Potentiating effects of GABA-induced membrane currents by DZP, HZ-166, CGS 
20625, TPA023B and NDMC on α2β3γ1GABAARs. (A) Concentration response curves of DZP, HZ-
166, CGS 20625, TPA023B and NDMC compared to the modulation of α2β3γ2GABAARS. (B) Efficacy 
of potentiation of GABA-induced current (EC5) by 10μM of each compound at α2β3γ1GABAARs. Data 
are mean ± SEM. n = 3 - 8 cells (C) GABA-evoked membrane currents of recombinant 
α2β3γ1GABAARs. Grey and black traces indicate before and during application of the BDZ, 
respectively. Scale bars 200 pA, 2s. 
Given the high efficacy elicited by HZ-166 at α2β3γ1GABAARs (Figure 6B-C), and the 
necessity of the presence of a γ subunit, we wondered whether this potentiation is dependent 
on the BDZ-binding site. We therefore investigated the potentiation of HZ-166 at α2β3γ1 and 
the BDZ-insensitive mutant α2(H-R)β3γ1 GABAARs. HZ-166 showed a strong decrease of 
efficacy in the point mutated receptors (Figure 7A-B). Moreover, when we expressed 
α1β2γ1GABAARs, the modulatory effects of HZ-166 were comparable to those found in α2 
point mutated receptors (Figure 7A-B). These results strongly suggest that the efficacy of 
potentiation by HZ-166 at γ1GABAARs depends on the BDZ-binding site at the α subunit and 
that, in the presence of the α1 subunit, the potentiation is virtually lost. Additionally, the 
inclusion of an α3 subunit in the receptor complex does not affect the modulatory effects of 
HZ-166 at γ1-containing GABAARs (Figure 7).   
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Figure 7. BDZ-binding site dependency of modulation by HZ-166. (A) Concentration response 
curve obtained for α2β3γ1, α3β3γ1, α1β3γ1 and α2(H-R)β3γ1 GABAARs. Data are mean ± SEM. 
Curves represent fits to Hill’s equation with a baseline fixed to 0. (B) GABA-evoked membrane 
currents of recombinant α1β2γ1 (grey and black), α2β3γ1 (light and dark red), α3β3γ1 (light and dark 
green) and α2(H-R)β3γ1 (light brown and dark brown) GABAARs. Light and dark traces represent 
before and during application of HZ-166 (10μM), respectively. Scale bars, 2 s and 200 pA. 
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DISCUSSION 
Targeting GABAA receptors is a new approach to restore spinal inhibition, which is a hallmark 
of persistent pain states. Moreover, there is increasing evidence from preclinical studies to 
suggest that non-sedative benzodiazepines with improved subunit selectivity exert 
antihyperalgesic actions. Indeed, strong antihyperalgesia with low sedative effects can be 
achieved by targeting α2-containing GABAARs and avoiding activity at α1GABAARs. My work 
has therefore focused on finding positive allosteric modulators for GABAARs with a high 
α2/α1 selectivity ratio. The classical BDZ-binding site of GABAARs lies at the interface 
between an α1, α2, α3, or α5 and the γ2 subunit. We first studied the potentiating effects of 
NDMC, which is the main metabolite of the licensed antiepileptic drug CBZ, and compared it 
to the effects of DZP. At saturating concentrations, DZP and CBZ potentiated α2 and 
α1GABAARs subtypes with similar efficacy, whereas NDMC clearly favored α2 over 
α1GABAARs. At low concentrations (< EC50), NDMC preferentially modulated with higher 
efficacy at α2GABAARs across the entire concentration range tested, whereas CBZ had 
similar effects on α2 and α1GABAARs and DZP favored α1GABAARs. Therefore, we show 
here that NDMC possesses an improved α2/α1 ratio. Our group has recently published these 
results together with an in vivo analysis of the pharmacological profile of NDMC (Ralvenius et 
al., 2016). We demonstrated that NDMC has a more favorable pharmacological profile than 
classical BDZ, suggesting that NDMC might represent a useful compound for initiating proof-
of-concept trials in healthy volunteers or chronic pain patients. 
A higher α2/α1 ratio was also evident for HZ-166. This compound showed higher potency 
and efficacy at α2 compared to α1 for all concentrations tested. HZ-166 has been shown to 
have antihyperalgesic actions in several chronic pain models (Di Lio et al., 2011, Paul et al., 
2014). Therefore, these in vivo effects can be directly related to the improved 
pharmacological profile at α2GABAARs. Thus HZ-166 might also be a good candidate for the 
study of BDZs as a therapeutic approach against chronic pain in humans.  
We also evaluated the modulatory activities of two novel BDZs, namely TP003 and 
TPA023B. TP003 has been shown to have anxiolytic effects in vivo, and acting specifically at 
α3GABAARs (Dias et al., 2005). However, conflicting evidence of its selectivity to 
α3GABAARs has been recently demonstrated (de Lucas et al., 2015). Therefore, in-house 
analysis of the modulatory effect of TP003 was required to develop further behavioral 
experiments in animal models. We have found that TP003 modulates all four GABAAR 
combinations, showing higher potency and efficacy at α3GABAARs. These results are in line 
with what has been published previously (de Lucas et al., 2015). The discrepancy with Dias 
and colleagues (2005) might come from the different expression system used (stably 
expressed mouse fibroblast L(tk-) cell lines in Dias et al., 2005). Dias and colleagues also 
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reported that binding affinities of TP003 at α1, α2, α3 and α5GABAARs are comparable (Dias 
et al., 2005), indicating that TP003 binds to the benzodiazepine-binding site and eventually 
exerts modulatory efficacy.  
TPA023B, a novel BDZ that has progressed to clinical trials (Russell et al., 2006), showed 
the strongest selectivity profile, with the best α2/α1 selectivity ratio and highest efficacy at α2 
and α3GABAARs. These results are in agreement with previous findings (Van Laere et al., 
2008, Atack et al., 2011). It has been previously shown that TPA023B shows a favorable 
pharmacokinetic profile. In phase I clinical trials it demonstrated a PK/PD profile suitable for 
dosing in human (Russell et al., 2006).  
Pharmacological enhancement of GABAergic synaptic inhibition in the spinal dorsal horn 
should have a beneficial effect on chronic pain syndromes that result from reduced 
presynaptic GABA release or from reduced responsiveness of postsynaptic GABAARs. 
However, one question arises on whether a potentiation of GABAergic responses will restore 
proper inhibition when glycinergic neurotransmission is also compromised. Most of inhibitory 
interneurons of the dorsal spinal cord co-release GABA and glycine (Todd and Sullivan, 
1990, Bohlhalter et al., 1996, Todd et al., 1996, Colin et al., 1998, Feng and Durand, 2005). 
Moreover, in cells in which no GABAergic component is noticeable under normal conditions, 
a GABAergic element can be revealed with benzodiazepines and neurosteroids (Keller et al., 
2001, Keller et al., 2004). Therefore, it is conceivable that pharmacological modulation of 
GABAergic transmission would also compensate for the reduction of glycinergic 
neurotransmission. 
It is well established that classical BDZs require the presence of α subunits (α1-3, 5) and the 
γ2 subunit for full potentiation of GABAARs. However, γ1-containing GABAARs still show 
sensitivity to certain BDZs (McKernan et al., 1995, Esmaeili et al., 2009). The γ1 subunit is 
rather restricted to certain brain nuclei, whereas the γ2 subunit is expressed throughout the 
brain with high levels in the cortex (Hortnagl et al., 2013). Current data from the Gensat 
Project provides evidence of the expression of the γ1 subunit in the spinal cord. It is thus 
necessary to confirm these data performing in-house Taq-man and/or immunohistochemical 
analysis. Enhancing the activity of GABAARs that express the γ1 subunit might avoid many 
supraspinally mediated BDZ effects and provide an extra level of specificity. I therefore 
aimed to characterize several novel BDZs in which we could find an increase of potency 
and/or efficacy targeting the α2 subunit (relevant for spinal-mediated analgesia) co-
expressed with the γ1 subunit in the GABAAR complex. Our data suggest that the best 
candidate was HZ-166 with efficacy values over 380%. The modulation of HZ-166 at 
α2β3γ1GABAARs was dependent on the BDZ-binding site at α subunit, and required the 
expression of the γ1 subunit. Additionally, HZ-166 showed reduced activity at 
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α1β2γ1GABAARs. However, the exchange of α2 to α3 in the receptor complex did not 
change the efficacy over the range of concentration tested.  
Taken together, these results support the effort of searching for new positive allosteric 
modulation acting preferentially at the α2/γ1 interface, which in turn will lead to an additional 
level of selectivity for analgesia at the spinal level, avoiding unwanted supraspinal effects. In 
addition, the data on HZ-166 show that this compound will be a useful tool to study a 
potential role of γ1-containing GABAARs in GABA mediated spinal analgesia.   
  
Experimental Section 
88 
 
REFERENCES 
Ahmadi, S., S. Lippross, W. L. Neuhuber and H. U. Zeilhofer (2002). "PGE(2) selectively 
blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn 
neurons." Nature neuroscience 5(1): 34-40. 
Atack, J. R., D. J. Hallett, S. Tye, K. A. Wafford, C. Ryan, S. M. Sanabria-Bohorquez, W. S. 
Eng, R. E. Gibson, H. D. Burns, G. R. Dawson, R. W. Carling, L. J. Street, A. Pike, I. 
De Lepeleire, K. Van Laere, G. Bormans, J. N. de Hoon, A. Van Hecken, R. M. 
McKernan, M. G. Murphy and R. J. Hargreaves (2011). "Preclinical and clinical 
pharmacology of TPA023B, a GABAA receptor &alpha;2/&alpha;3 subtype-selective 
partial agonist." Journal of psychopharmacology 25(3): 329-344. 
Besson, M., Y. Daali, A. Di Lio, P. Dayer, H. U. Zeilhofer and J. Desmeules (2013). 
"Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model 
in mice: a pharmacokinetic-pharmacodynamic study." Basic & clinical pharmacology 
& toxicology 112(3): 192-197. 
Bohlhalter, S., O. Weinmann, H. Mohler and J. M. Fritschy (1996). "Laminar 
compartmentalization of GABAA-receptor subtypes in the spinal cord: an 
immunohistochemical study." The Journal of neuroscience : the official journal of the 
Society for Neuroscience 16(1): 283-297. 
Colin, I., P. Rostaing, A. Augustin and A. Triller (1998). "Localization of components of 
glycinergic synapses during rat spinal cord development." The Journal of comparative 
neurology 398(3): 359-372. 
Coull, J. A., S. Beggs, D. Boudreau, D. Boivin, M. Tsuda, K. Inoue, C. Gravel, M. W. Salter 
and Y. De Koninck (2005). "BDNF from microglia causes the shift in neuronal anion 
gradient underlying neuropathic pain." Nature 438(7070): 1017-1021. 
Coull, J. A., D. Boudreau, K. Bachand, S. A. Prescott, F. Nault, A. Sik, P. De Koninck and Y. 
De Koninck (2003). "Trans-synaptic shift in anion gradient in spinal lamina I neurons 
as a mechanism of neuropathic pain." Nature 424(6951): 938-942. 
de Lucas, A. G., P. K. Ahring, J. S. Larsen, I. Rivera-Arconada, J. A. Lopez-Garcia, N. R. 
Mirza and G. Munro (2015). "GABAA alpha5 subunit-containing receptors do not 
contribute to reversal of inflammatory-induced spinal sensitization as indicated by the 
unique selectivity profile of the GABAA receptor allosteric modulator NS16085." 
Biochemical pharmacology 93(3): 370-379. 
Di Lio, A., D. Benke, M. Besson, J. Desmeules, Y. Daali, Z. J. Wang, R. Edwankar, J. M. 
Cook and H. U. Zeilhofer (2011). "HZ166, a novel GABAA receptor subtype-selective 
benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and 
neuropathic pain." Neuropharmacology 60(4): 626-632. 
Dias, R., W. F. Sheppard, R. L. Fradley, E. M. Garrett, J. L. Stanley, S. J. Tye, S. Goodacre, 
R. J. Lincoln, S. M. Cook, R. Conley, D. Hallett, A. C. Humphries, S. A. Thompson, K. 
A. Wafford, L. J. Street, J. L. Castro, P. J. Whiting, T. W. Rosahl, J. R. Atack, R. M. 
McKernan, G. R. Dawson and D. S. Reynolds (2005). "Evidence for a significant role 
of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of 
benzodiazepines." The Journal of neuroscience : the official journal of the Society for 
Neuroscience 25(46): 10682-10688. 
Draguhn, A., T. A. Verdorn, M. Ewert, P. H. Seeburg and B. Sakmann (1990). "Functional 
and molecular distinction between recombinant rat GABAA receptor subtypes by 
Zn2+." Neuron 5(6): 781-788. 
Esmaeili, A., J. W. Lynch and P. Sah (2009). "GABAA receptors containing gamma1 
subunits contribute to inhibitory transmission in the central amygdala." Journal of 
neurophysiology 101(1): 341-349. 
Feng, Z. and D. M. Durand (2005). "Decrease in synaptic transmission can reverse the 
propagation direction of epileptiform activity in hippocampus in vivo." Journal of 
neurophysiology 93(3): 1158-1164. 
  Experimental Section 
89 
 
Fritschy, J. M. and I. Brunig (2003). "Formation and plasticity of GABAergic synapses: 
physiological mechanisms and pathophysiological implications." Pharmacology & 
therapeutics 98(3): 299-323. 
Harvey, R. J., U. B. Depner, H. Wassle, S. Ahmadi, C. Heindl, H. Reinold, T. G. Smart, K. 
Harvey, B. Schutz, O. M. Abo-Salem, A. Zimmer, P. Poisbeau, H. Welzl, D. P. Wolfer, 
H. Betz, H. U. Zeilhofer and U. Muller (2004). "GlyR alpha3: an essential target for 
spinal PGE2-mediated inflammatory pain sensitization." Science 304(5672): 884-887. 
Hortnagl, H., R. O. Tasan, A. Wieselthaler, E. Kirchmair, W. Sieghart and G. Sperk (2013). 
"Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the 
mouse brain." Neuroscience 236: 345-372. 
Keller, A. F., S. Beggs, M. W. Salter and Y. De Koninck (2007). "Transformation of the output 
of spinal lamina I neurons after nerve injury and microglia stimulation underlying 
neuropathic pain." Molecular pain 3: 27. 
Keller, A. F., J. D. Breton, R. Schlichter and P. Poisbeau (2004). "Production of 5alpha-
reduced neurosteroids is developmentally regulated and shapes GABA(A) miniature 
IPSCs in lamina II of the spinal cord." The Journal of neuroscience : the official journal 
of the Society for Neuroscience 24(4): 907-915. 
Keller, A. F., J. A. Coull, N. Chery, P. Poisbeau and Y. De Koninck (2001). "Region-specific 
developmental specialization of GABA-glycine cosynapses in laminas I-II of the rat 
spinal dorsal horn." The Journal of neuroscience : the official journal of the Society for 
Neuroscience 21(20): 7871-7880. 
Khom, S., I. Baburin, E. N. Timin, A. Hohaus, W. Sieghart and S. Hering (2006). 
"Pharmacological properties of GABAA receptors containing gamma1 subunits." 
Molecular pharmacology 69(2): 640-649. 
Knabl, J., R. Witschi, K. Hosl, H. Reinold, U. B. Zeilhofer, S. Ahmadi, J. Brockhaus, M. 
Sergejeva, A. Hess, K. Brune, J. M. Fritschy, U. Rudolph, H. Mohler and H. U. 
Zeilhofer (2008). "Reversal of pathological pain through specific spinal GABAA 
receptor subtypes." Nature 451(7176): 330-334. 
McKernan, R. M., K. Wafford, K. Quirk, K. L. Hadingham, E. A. Harley, C. I. Ragan and P. J. 
Whiting (1995). "The pharmacology of the benzodiazepine site of the GABA-A 
receptor is dependent on the type of gamma-subunit present." Journal of receptor and 
signal transduction research 15(1-4): 173-183. 
Mohler, H., J. M. Fritschy and U. Rudolph (2002). "A new benzodiazepine pharmacology." 
The Journal of pharmacology and experimental therapeutics 300(1): 2-8. 
Moore, K. A., T. Kohno, L. A. Karchewski, J. Scholz, H. Baba and C. J. Woolf (2002). "Partial 
peripheral nerve injury promotes a selective loss of GABAergic inhibition in the 
superficial dorsal horn of the spinal cord." The Journal of neuroscience : the official 
journal of the Society for Neuroscience 22(15): 6724-6731. 
Munro, G., H. K. Erichsen, M. G. Rae and N. R. Mirza (2011). "A question of balance--
positive versus negative allosteric modulation of GABA(A) receptor subtypes as a 
driver of analgesic efficacy in rat models of inflammatory and neuropathic pain." 
Neuropharmacology 61(1-2): 121-132. 
Paul, J., G. E. Yevenes, D. Benke, A. Di Lio, W. T. Ralvenius, R. Witschi, L. Scheurer, J. M. 
Cook, U. Rudolph, J. M. Fritschy and H. U. Zeilhofer (2014). "Antihyperalgesia by 
alpha2-GABAA receptors occurs via a genuine spinal action and does not involve 
supraspinal sites." Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology 39(2): 477-487. 
Pernia-Andrade, A. J., A. Kato, R. Witschi, R. Nyilas, I. Katona, T. F. Freund, M. Watanabe, 
J. Filitz, W. Koppert, J. Schuttler, G. Ji, V. Neugebauer, G. Marsicano, B. Lutz, H. 
Vanegas and H. U. Zeilhofer (2009). "Spinal endocannabinoids and CB1 receptors 
mediate C-fiber-induced heterosynaptic pain sensitization." Science 325(5941): 760-
764. 
Ralvenius, W. T., M. A. Acuna, D. Benke, A. Matthey, Y. Daali, U. Rudolph, J. Desmeules, H. 
U. Zeilhofer and M. Besson (2016). "The clobazam metabolite N-desmethyl clobazam 
Experimental Section 
90 
 
is an alpha2 preferring benzodiazepine with an improved therapeutic window for 
antihyperalgesia." Neuropharmacology 109: 366-375. 
Ralvenius, W. T., D. Benke, M. A. Acuna, U. Rudolph and H. U. Zeilhofer (2015). "Analgesia 
and unwanted benzodiazepine effects in point-mutated mice expressing only one 
benzodiazepine-sensitive GABAA receptor subtype." Nature communications 6: 6803. 
Rivas, F. M., J. P. Stables, L. Murphree, R. V. Edwankar, C. R. Edwankar, S. Huang, H. D. 
Jain, H. Zhou, S. Majumder, S. Sankar, B. L. Roth, J. Ramerstorfer, R. Furtmuller, W. 
Sieghart and J. M. Cook (2009). "Antiseizure activity of novel gamma-aminobutyric 
acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat 
models." Journal of medicinal chemistry 52(7): 1795-1798. 
Russell, M. G., R. W. Carling, L. J. Street, D. J. Hallett, S. Goodacre, E. Mezzogori, M. 
Reader, S. M. Cook, F. A. Bromidge, R. Newman, A. J. Smith, K. A. Wafford, G. R. 
Marshall, D. S. Reynolds, R. Dias, P. Ferris, J. Stanley, R. Lincoln, S. J. Tye, W. F. 
Sheppard, B. Sohal, A. Pike, M. Dominguez, J. R. Atack and J. L. Castro (2006). 
"Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective 
agonists for the treatment of anxiety." Journal of medicinal chemistry 49(4): 1235-
1238. 
Scott-Stevens, P., J. R. Atack, B. Sohal and P. Worboys (2005). "Rodent pharmacokinetics 
and receptor occupancy of the GABAA receptor subtype selective benzodiazepine 
site ligand L-838417." Biopharmaceutics & drug disposition 26(1): 13-20. 
Smart, T. G., S. J. Moss, X. Xie and R. L. Huganir (1991). "GABAA receptors are 
differentially sensitive to zinc: dependence on subunit composition." British journal of 
pharmacology 103(4): 1837-1839. 
Todd, A. J. and A. C. Sullivan (1990). "Light microscope study of the coexistence of GABA-
like and glycine-like immunoreactivities in the spinal cord of the rat." The Journal of 
comparative neurology 296(3): 496-505. 
Todd, A. J., C. Watt, R. C. Spike and W. Sieghart (1996). "Colocalization of GABA, glycine, 
and their receptors at synapses in the rat spinal cord." The Journal of neuroscience : 
the official journal of the Society for Neuroscience 16(3): 974-982. 
Van Laere, K., G. Bormans, S. M. Sanabria-Bohorquez, T. de Groot, P. Dupont, I. De 
Lepeleire, J. de Hoon, L. Mortelmans, R. J. Hargreaves, J. R. Atack and H. D. Burns 
(2008). "In vivo characterization and dynamic receptor occupancy imaging of 
TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a 
partial agonist." Biological psychiatry 64(2): 153-161. 
Wieland, H. A., H. Luddens and P. H. Seeburg (1992). "Molecular determinants in 
GABAA/BZ receptor subtypes." Advances in biochemical psychopharmacology 47: 
29-40. 
Witschi, R., P. Punnakkal, J. Paul, J. S. Walczak, F. Cervero, J. M. Fritschy, R. Kuner, R. 
Keist, U. Rudolph and H. U. Zeilhofer (2011). "Presynaptic alpha2-GABAA receptors 
in primary afferent depolarization and spinal pain control." J Neurosci 31(22): 8134-
8142. 
Zhang, Z., Y. Q. Cai, F. Zou, B. Bie and Z. Z. Pan (2011). "Epigenetic suppression of GAD65 
expression mediates persistent pain." Nature medicine 17(11): 1448-1455. 
 
 
  
  Experimental Section 
91 
 
 
	
   
General Discussion 
92 
 
4.	General	Discussion	and	Out‐Look	
In pharmacology, the therapeutic window refers to a dose range in which there are few or no 
side effects. Adding degrees of selectivity of a drug for a specific target, it is then conceivable 
to increase the therapeutic window. Therefore, the main goal of this thesis was to identify 
compounds and targets that allow a specific or at least preferential action on the nociceptive 
system. 
The results summarized in Chapter I provide evidence for the first time that a high level of 
specificity can be achieved by targeting synaptic glycine receptors in the phosphorylated 
state, which are key contributors to spinal inflammatory pain sensitization. Un-primed 
recombinant α3/β GlyRs are not sensitive to the test compound 2,6-di-tert-butylphenol (2,6-
DTBP). However, by exchanging the serine in the PKA consensus phosphorylation site 
(S346) to a negatively charged amino acid (S346E), α3(S346E)βGlyRs became sensitive to 
modulation by 2,6-DTBP. Furthermore, we confirmed that synaptic (presumable α3/β) GlyRs 
are sensitive to 2,6-DTBP only after exposure to PGE2, which leads to PKA dependent 
phosphorylation of GlyRα3. Moreover, mice treated with 2,6-DTBP did not develop impaired 
locomotor activity, motor coordination or muscle strength. Strikingly, 2,6-DTBP showed anti-
hyperalgesic effects in inflammatory pain models. These effects were significantly decreased 
in mice lacking the GlyRα3 subunit, indicating a central role of α3GlyR in the anti-
hyperalgesic actions of 2,6-DTBP.  
Post-translational modifications – such as phosphorylation – can promote a global 
conformational change of pentameric ligand-gated ion channels. Phosphorylation-induced 
conformational changes in the α3GlyR have been recently reported using voltage clamp 
fluorometry (Han et al., 2013). This technique is based on changes in the quantum efficiency 
of fluorophores covalently bound to a cysteine introduced into the domain of interest. It has 
been shown that phosphorylation at S346 of the GlyRα3 subunit promotes a change of 
fluorescence in the signal when the fluorophore is linked to the glycine-binding site (Han et 
al., 2013). These results indicate that a conformational change propagates from the M3-M4 
intracellular loop to the agonist- binding site located at about 80Å. Therefore, it is tempting to 
speculate that, if phosphorylation alters the structure of orthosteric and/or allosteric binding 
sites, then binding of a drug to a phosphorylated-“primed” receptor may compensate for the 
effects of the phosphorylation (Talwar and Lynch, 2014). 
During the last two years there have been increasing efforts to develop new compounds 
targeting GlyRs (Eckle et al., 2014, Farley and Mihic, 2015, Maleeva et al., 2015b, a, Shalaly 
et al., 2015, Breitinger and Breitinger, 2016, Breitinger et al., 2016, Cornelison et al., 2016, 
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Germann et al., 2016, Lara et al., 2016, Yin et al., 2016). Moreover, researchers at Neusentis 
(Granta Park, Great Abington, Cambridgeshire, UK) have validated the use of a high-
throughput fluorescent membrane potential screening for the development of new positive 
allosteric modulators of α3GlyRs as novel analgesic (Stead et al., 2016). These techniques 
will help the functional characterization of compounds with high efficacy and potency acting 
at GlyRs in an efficient manner. However, despite the fact that using high-throughput 
screening leads to the identification of hit compounds much faster than conventional 
approaches, the screening operation also gives low genuine hit rate and a large number of 
false positives (Jensen and Kristiansen, 2004, Ghisdal et al., 2014). This point encourages 
the use of conventional techniques, such as manual patch-clamp, to verify possible true 
candidates. The work of the Neusentis team has shown that one compound (compound Nr. 2 
in (Stead et al., 2016)), which was tested at homomeric GlyRs, shows high efficacy at 
α3GlyR and α1GlyRs in the absence of activity at GABAARs (α1β2γ2). It is at present 
unknown whether this compound exerts analgesic effects in vivo.  
A relevant question is whether the enhancement of spinal inhibitory neurotransmission has a 
real impact on pain treatment in humans. The α3 subunit of the GlyR has two isoforms in 
human. Both isoforms, named “a” and “b” (RefSeq: NP_001036008.1 and NP_006520.2, 
respectively), have a consensus sequence for recognition and phosphorylation by PKA at the 
serine residue (Arg-Glu-Ser-Arg). Although, to our knowledge, there is no information in 
human tissue of an inhibition of α3GlyRs upon activation of EP2 receptor, the mechanism 
underlying a PGE2-mediated sensitization may be the same as in mice. Moreover, GlyR 
distribution in human tissue is similar to the distribution in the rodent spinal cord, as judged 
by immunostaining post-mortem tissue (reviewed in Baer et al., 2009). Therefore, targeting 
specifically those inflammation-primed GlyRs in humans might be a promising target to 
alleviate inflammatory pain. 
Our data provide evidence on the molecular determinants for binding of 2,6-DTBP at the 
GlyRα3. We identify that the phenylalanine at the position 388 (F388) is required for 
modulatory actions of 2,6-DTBP at homomeric α3GlyRs. This residue is also necessary for 
the modulation of propofol at homomeric α1GlyRs (Moraga-Cid et al., 2011). Potentiation of 
propofol at GABAARs occurs with about 8-times higher potency (Pistis et al., 1997) than that 
of homomeric α1GlyRs and α3GlyRs. This low potency displayed in our in vitro studies 
reflects the high doses of 2,6-DTBP used to achieve antihyperalgesic effects in vivo. 
Furthermore, 2,6-DTBP evoked analgesia not only through α3GlyRs  but also through other 
targets. Therefore, in order to test whether our findings in mouse pain models are relevant to 
human pain condition, compounds need to be developed with increased potency at 
phosphorylated a3GlyR and reduced off-target effects.  
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Phosphorylation of the GlyRα3 subunit does not only occur in inflammatory pain states. 
Instead, it also controls rhythmic breathing (Manzke et al., 2010). Serotonin induces a de-
phosphorylation of α3GlyRs at S346 – thereby enhancing glycinergic activity – through an 
activation of the serotonin receptor 5-HTR1A. Stimulation of this pathway reverses opioid-
induced respiratory depression, suggesting that enhancing the activity of phosphorylated 
α3GlyR might remedy this respiratory alteration. Therefore, it is tempting to speculate that a 
selective potentiation of phosphorylated-primed α3GlyRs might not only restore inflammatory 
mediated spinal disinhibition, but also could affect some others mechanisms involving the 
phosphorylation and eventual reduction of glycinergic inhibition. 
Can a high level of specificity be reached targeting GABAARs? 
The results in Chapter II provide evidence that certain benzodiazepine site agonists or 
partial agonists (namely NDMC, HZ-166 and TPA023B) show a more favourable α2 over α1 
activity. Pre-clinical studies suggest that such compounds should be well-suited for the 
treatment of persistent pain (Knabl et al., 2008, Di Lio et al., 2011, Paul et al., 2014, 
Ralvenius et al., 2015). To increase the level of specificity of a potential drug, we decided to 
explore of the γ subunit subtype as an additional way to increase specificity. In the brain, the 
γ1-subunit is expressed only in very low levels whereas some data from public website and 
from our group suggest a higher expression level in the dorsal horn. I had therefore decided 
to determine the efficacy at γ1 GABAARs of selected BDZ site ligands with a favourable 
α2/α1 or analgesia/sedation ratio. Among the compounds tested HZ-166 had the most 
promising γ1/γ2 activity ratio α2GABAARs. On-going experiments in our group use this 
knowledge to test γ1 containing GABAARs make a relevant contribution to spinal analgesia 
by HZ-166. A reasonable way to test whether HZ-166 exerts an in vivo effect at γ1GABAARs 
is to knock-out the γ2 subunit at spinal level. This can be done taking advantage of the 
Hoxb8-cre mouse line (Witschi et al., 2010), and crossing it with γ2-floxed animals. 
According to the results described in this thesis, HZ-166 might thus have antihyperalgesic 
effects, acting at γ1GABAARs. 
A recent publication has shed light on the composition of GABAARs in the human spinal cord 
(Waldvogel et al., 2010). The expression of α1-3 subunits together with β2/3 subunits and the 
γ2 subunit is similar to levels found in rodents (Paul et al., 2012, Ralvenius et al., 2015). 
Additionally, recent studies have provided direct evidence for BDZ-mediated analgesia in 
human volunteers (Vuilleumier et al., 2013, Besson et al., 2015). However, those effects 
were mild and still accompanied by sedation. In mice, it has been recently described by our 
group that ED50 values (the effective dose at which 50% of the maximal effect is reached) of 
DZP for sedation and antihyperalgesia are different by a factor of about 20 (Ralvenius et al., 
2015). These data indicate that such a difference underlies the dose-limiting sedative effects 
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of non-selective BDZs. Hence, selectively targeting α2GABAARS might have the best benefit-
risk ratio producing pronounced antihyperalgesic effects in the absence of sedation. Our 
study in recombinant GABAARs has shown that NDMC may have a better profile than a non-
selective BDZ. These results translated into in vivo improved therapeutic window of NDMC 
over DZP (Ralvenius et al., 2016). Moreover, using HZ-166 as a pharmacological tool 
targeting α2 and γ1-containing GABAARs, we provide evidence for the first time of an 
increased level of specificity not only at a higher α2/α1GABAAR ratio, but also at a higher 
γ1/γ2 ratio.  
Most drug discovery efforts in the benzodiazepine field have been into dedicated screening 
libraries for the development of compounds acting at the canonical benzodiazepine-binding 
site. These endeavors are conceivable, as γ2-containing receptors form the vast majority of 
GABAARs in the brain and mediate most if not all therapeutic effects of classical 
benzodiazepines. As shown in this thesis and by others, some of these compounds also act 
at γ1GABAARs albeit with lower potency. To the best of my knowledge, no screening effort 
has been undertaken specifically targeted at γ1GABAARs. 
In summary, the results presented in this thesis identified new mechanisms for a specific 
interaction with inhibitory neurotransmitter receptors involved in the spinal control of pain. 
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